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Acquired immunodeficiency syndrome (AIDS) is a disease caused by the 
suppression of immune system. The disease is transmitted through body fluid 
contact. The causative agent is an retrovirus known as human immunodeficiency 
virus. Three important enzymes involved in its life cycle are potential targets for 
anti-AIDS therapy. They are the HP/ reverse transcriptase (mV RT), HD/ 
integrase (HD/ EM) and HIV protease (HIV PR). Several synthetic compounds 
have been approved for the treatment of AIDS. On the other hand, some natural 
products isolated from plant were shown to have potent anti-HIV activities. Ln this 
study, thirteen traditional Chinese medicinal herbs which have anti-infective 
properties were used for screening of inhibition on HTV RT activity. The aqueous 
extract of Prunella vulgaris exhibited the highest HrV RT inhibitory activity in 
vitro. It was chosen for further isolation and characterization. The crude extract 
was further purified by several chromatographic techniques. The purified extract 
was found to be dose-related. Chemical analysis indicated that the active 
constituents may contain polyphenolic compounds. The purified extracts were also 
potent inhibitors of Taq polymerase and Superscript II indicating that the active »• 
components may target generally to DNA polymerase. On the other hand, 
recombinant HIV protease was expressed and the activity was demonstrated by 
both the HPLC assay method and the fluorometric method. Screening of thirteen 
herbal extracts showed that the methanol extract of Woodwardia unigemmata and 
aqueous extract of Prunella vulgaris have the highest inhibition to HFV protease. 
Both extracts were chosen for further characterization. Both extracts were dose-
related. These results showed that natural products isolated from traditional 




















Chapter 1 Introduction 
1.1 Acquired immunodeficiency syndrome 
1.1.1 Discovery ofAIDS 
]n the June of 1981，five young men were diagnosed with Pneumocystis 
carinii pneumonia, a disease only found in people whose immune system had been 
suppressed by drug and disease. In the next month, 26 gay men were diagnosed with 
Kaposi's sarcoma, an uncommon skin cancer usually occurred in older men of 
Hebrew or Italian. The incidence of these cases indicated that a novel 
immunodeficiency disease was spreading among the homosexuals as well as drug 
users. This disease is now well known as the Acquired krununodeficiency 
Syndrome (AIDS) (Stine et al., 1996). 
1.1.2 Definition and symptoms ofAIDS 
AIDS is a disease that is caused by suppression of the immune system. In 
January 1993，the Centers of Disease Control Prevention proposed a definition on 
AIDS. It includes all identified AIDS defining illnesses and CD4 lymphocyte 
counts. All patients with CD4 counts less than 200 cells / mm] (or CD4 percentage 
< 14), and three AEDS defining conditions, namely, pulmonary tuberculosis, 
invasive cerivcal cancer, and recurrent bacterial pneumonia (Center for Disease 
Control, 1993). 
AIDS can be separated into three stages. The first one is early short-term, or 
acute stage. Then is the middle stage, or chronic/latent stage and finally, the AIDS 
stage. Acute stage lasts for 1 to 2 weeks where CD4 cell count range is 1000 - 5000 
1 
cells / n W (Saag, 1994). It is characterized by fever, headache, nausea, anorexia, 
fatigue, sweaters sore throat and dry cough (Stine et al., 1996). Chronic/latent stage 
lasts for 8 -10 years (Stine et al., 1996). CD4 cell count range is 750-500 cells/mm^ 
(Saag, 1994). No symptom can be found in this stage. Finally is the AIDS stage. 
This stage lasts for 1 - 2 years and CD4 cell count range drops from 500 cells/mm^ 
to 0 cells/ mm^ Several clinical signs can be found such as tuberculosis, 
lymphadenopathy, Kaposi's sarcoma, mouth and esophagus pain and odynophagia 
and CNS lymphoma, etc. (Saag, 1994). 
1.1.3 AIDS transmission 
The incidence of AIDS was first occurred in homosexual men and injection 
drug users. AIDS was subsequently found in those receiving blood product, drug 
addicts using needle for injection of drugs or heterosexual female partner of AIDS 
patients. It was found that a virus, called human immunodeficiency virus (HrV), 
was transmitted through body fluid exchange during intimate sexual contact, 
contaminated needles and contaminated blood or blood products. There are several 
*  
routes for HTV transmission. The transmission of HIV vims can be through blood 
inoculation such as transfusion ofHIV-infected blood and blood products, needles 
sharing among injection drug user, needlesticks, open cuts and mucous membrane 
exposure in healthcare worker and the use of HrV-contaminated skin-piercing 
instruments (ears, acupuncture, tattoos). It can also be transmitted through sexual 
contact where exchange of semen, vaginal fluids or blood happened such as 
homosexual, lesbian, heterosexual and bisexual men. Finally, the perinatal route in 
which HP/ can be transmitted through intrauterine, peripartum and breast feeding 
(Friedlandera/., 1996). 
2 
1.1.4 AIDS epidemic 
UNAIDS and WHO estimated that over 30 million people are living with 
HIV infection at the end of 1997. One point one million are children under the age 
of 15，90% of them live in the developing countries. It was also estimated that 
16,000 new infection everyday in the year. Two point three million died from AIDS 
in 1997. 46% were women and 2% were children. It was also shown that the 
number of people with HrV/AIDS in Africa, South & South-East Asia and Latin 
America were much higher than other region which is 20.1 million, 6 million and 
1.3 million respectively (December 1997 by UNAIDS and WHO). 
In Hong Kong, the number of new cases of HIV infection in 1997 has 
increased by about 30% compared to the previous year. The number of HIV 
infection was 181 and 64 developed AIDS. In these cases, 146 were male and 35 
were female patient. Most of these HIV-infected patients engaged in heterosexual 
activities (February 1998，AIDS Unit, Department ofHealth, Hong Kong). 
t-
1.2 Human immunodeficiency virus 
1.2.1 Discovery ofHIV 
The first indication that AIDS could be caused by a retrovirus came in 1983. 
A T-cell leukemia virus was firstly suspected to infect patient with severe 
immunodeficiency (Barre-Sinoussi et cd., 1983). However, it seemed unlikely 
because of its poor replication in cell culture (Poiesz et al., 1980). Montagnier and 
coworker were the first group successfully isolated a virus which they called the 
lymphadenopathy-associated virus (LAV) in 1983 (Montagnier et al., 1984). One 
^ 
i 
year later, Gallo and his co-workers reported another human retrovirus other than 
HTLV isolated from peripheral blood mononuclear cells of adult and pediatric 
AIDS patients. They named this virus as HTLV-III (Popovic et al, 1984). At that 
time Levy and coworkers also reported the virus named AIDS-associated retrovirus 
(ARV) recovered from AIDS patients (Levy, et al., 1984). The three viruses were 
found to be the same group of retroviruses and their properties identified as 
lentivirinae. Li 1986, the virus was given a separated name, the human 
immunodeficiency virus (HIV) (Coffin et al, 1986). 
1.2.2 The structure ofHIV 
HIV-1 is a retrovirus belonging to the family of Retroviridae. The virus is 
surrounded by lipid bilayer with two major glycoproteins, gp41 and gpl20. The 
core of virion contain matrix (pl7)，capsid (p24) and neucleocapsid Q)7) proteins. 
There are two copies of RNA. The viral enzymes reverse transcriptase, integrase 
and protease are also in the virion core (Connor et al., 1997). (Figure 1.1 A, 1.1 B ) 翁m 
^ *^ 發 ^  •'  �‘‘ 
(A) (B) 
Figure 1.1 (A) Schematic diagram of the component of the HFV-1 virion. (B) 
electron micrograph of the HIV-1 virion. (Photo courtesy of H. 
Gelderblom). 
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1.2.3 Genomic structure ofHIV 
The genomic size ofHIV is about 9.8 kb and it is translated into gag and pol 
protein. The gag precursor is cleaved to form five virion core proteins. They are p9, 
p25, pl7, pl and p6 (Henderson et al., 1992). The pol protein is cleaved to form 
reverse transcriptase (RT), integrase (IN) and protease (PR), gpl20 and gp41 
glycoproteins are produced from env together with some regulatory proteins (Levy 
et aL, 1994). (Figure 1.2) 
HIV-1 _ _ _ rev uc 
LTR gag pol vif vpu vpr tat rev cnv ncf LTR 
I ' . , I I I I I I I _ n I I _ E ^ 1 _ J ,', ' , ‘ P24 pl6 pl5 pl4 pl9/20 I gpl60 | p28 p 11 poo/j 1 pj2 1 • 
I ~ ~ ~ I r ^ 
Pl7 P24 Pl5 gpl20 gp41 
Figure 1.2 Diagram of the HIV-1 genome and encoded proteins. 
1.2.4 Lifecycle of f f lV 
r 
The major target cell for HIV infection is CD-4 T-lymphocytes of the 
immune system (Dalgleish et aL, 1984). The replication ofHIV is initiated by the 
attachment of virus on the target cell through interaction of gpl20 glycoprotein. The 
attachment causes the conformational change so that the gp 41 viral envelope 
glycoprotein interacts with the host cell membrane (Moore et aL, 1993). The virus 
is uncoated in the cell cytoplasm. Reverse transcription is then proceeded that viral 
RNA is converted into a double-stranded DNA copy. The viral DNA copy is then 
5 
translocated to the host nucleus and integrated into host chromosomal DNA by viral 
integrase (Bushman et al., 1990). When activation ofHTV transcription initiated as 
happened in the early stage, a 2 kb message is transcribed and subsequently 
translated to produce essential viral proteins such as Tat, Rev and Nef. Rev is then 
transported into cytoplasm and processed into structural and enzymatic viral protein 
(Schwartz etaL, 1990). 
The HrV RNA, modified virus proteins and enzymes are then assembled to 
form a virion core. Gag-pol polypeptide dimerizes and converts into active HIV 
protease. The function of which is to cleave the precursor protein to generate 
ribonucleoprotein core. The final step is maturation (Kaplan et al., 1994). The 
matured virion are formed by budding through the host cell plasma membrane. At 
that time they acquire gpl20 and gp41 envelope glycoproteins. The released virus 
are ready for another round of infection to healthy CD4+ T-lymphocytes (Figure 
" ) . : ¾ 
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Figure 1.3 Life cycle ofHIV-1 
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1.2.5 How HIV is involved in different stages ofAIDS 
La the early/short-term stage, it is characterized by the high level of virus 
replication. The level of circulating HIV-1 may reach 10^ particle/ml plasma (Piatak 
et al., 1993). HFV-1 specific antibodies are developed in this stage and the virion 
level in circulation eventually decrease, indicating that the host immune system is 
effective, to. chronic / latent stage, low level of HTV-1 in peripheral blood is found. 
However, it doesn't mean that viral replication is low (Connor et al., 1997). The 
evidence shows that HTV-l RNA is present in plasma at all stage of infection and, 
with sensitive RNA based method of detection, shows a rapid turnover of free 
virion (Ho,1997). Li the AIDS stage, virion particle increases due to the depletion of 
CD4 cells. Abnormal CD4 /CD8 cell ratio can be found (Figure 1.4). 
seroconversion AIDS 
CD4+ cell5 
" ^ x ^ ^ ^ 
A \ ^ 
/ \ HIY RNA ^ > < r 
/ • \ 
L_j 1 1 1 1 r'f-
1 2 3 4 5 6 
Months after infection Years after infection 
Figure 1.4 Changes in HTV-1 RNA levels and CD4 T cells during the course of 
fflV-1 infection. 
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1.3 Therapeutic target sites for treatment ofAIDS 
Every step involved in the life cycle of HFV can be considered as the putative 
target site to stop the replication of HIV, such as the attachment of gpl20 to CD4 
T-lymphocyte, inhibition of HIV reverse transcriptase, HIV integrase, HFV 
protease and post-translational modification. Several drugs have been found to be 
active in interfering the attachment of the virus. To date, the most common drugs 
for treatment of AE)S are inhibitors against HTV reverse transcriptase and HIV 
protease. 
1.3.1 HIV reverse transcriptase OHIV RT) 
Reverse transcriptase is a DNA polymerase that is not only able to synthesize 
DNA, but also able to copy from an RNA template. The retroviral reverse 
transcriptase was first discovered by David Baltimore in 1970 (Baltimore, 1970) 
and the discovery ofHIV in 1983 led to a dramatic increase in research of reverse 
transcriptase in this class of virus. 
r 
HIV reverse transcriptase plays an important role in HrV replication. Li the 
early stage of viral replication, the enzyme is responsible for converting viral RNA 
into double-stranded proviral DNA. It is a heterodimer with 2 subunits called p51 
and p66 (Restle et al.’ 1990). p66 contains DNA polymerase and RNase H activity 
while p51 has only DNA polymerase activity (Hansen et al., 1988). Three steps 
are involved in the reverse transcription process. The first step is the formation of 
RNA-DNA hybrid by RNA-dependent DNA polymerase activity ofHIV RT. Then, 
the RNA template is removed by intrinsic RNaseH activity of the HIV RT. Finally, 
8 
the short fragment viral RNA directs the plus strand DNA synthesis (Devico, et aL, 
1992). 
Several compounds were found to be effective in inhibiting HIV RT. These 
compounds can be divided into two groups, the nucleoside inhibitors and the non-
nucleoside inhibitors. Nucleoside inhibitors are a broad family of 2',3'-
dideoxynucleosides. This group include 3 ‘ -azido-2‘ ,3 ‘ -dideoxynucleoside (AZT), 
2',3'-dideoxyinosine (ddI) (Mitsuya et al., 1986), 2',3'-dideoxycytidine (ddC) 
(Merigan et al., 1989), 2‘,3‘-didehydro-2‘,3‘-dideoxythymidine (d4T) and 2',3'-
dideoxy-3'-thaicytidine (3TC) (Greenberg et cd., 1990). 
The nucleoside analog itself is not effective to inhibit the enzyme. The 
inhibitor should be in triphosphate form of that nucleoside. For example, AZT 
first diffuses across human lymphocyte and phosphorylated at the 5’ position to 
form AZT triphosphate by thymidine kinase, thymidylate kinase and other cellular 
enzymes which phosphorylate thymidine. The phosphorylated form then 
incorporates into viral DNA, losing two phosphates so that the monophosphate 
AZT replaces the structurally similar thymidine monophosphate. The replacement 
of normal nucleoside by nucleoside analog is the main mechanism of the action 
(Furman etal., 1986). 
Another group of chemicals are non-nucleoside inhibitors. Non-nucleoside 
inhibitors are a group of compounds that are different in structures but have 
common mechanism of action. The drug binds to a common site on the enzyme. 
Many of these inhibitors are derived from natural products (Emini, 1996). The 
non-nucleoside inhibitors are highly selective. They can't inhibit HIV-2 reverse 
9 
transcriptase or other viral and cellular polymerase (Sandstrom, 1993). Moreover, 
they do not require metabolic activation to manifest their antiviral effects. It is 
commonly used in combination with various nucleoside analog inhibitors or with 
anti-HrV-1 protease inhibitors (Emini, 1996). 
The first compound of this category reported to be effective in inhibiting 
HIV-RT is tetrahydroimidazo[4,5,l-jk][ 1,4]-benzodiazepin-2(lH)-one (TIBO) 
derivatives. The first compound to be tested in patient was R-82913 (White et al., 
1991). Several groups of non-nucleoside inhibitors had been developed later on. 
For example, bisheteroarylpiperazine (BHAP) derivatives U-90152 (Dueweke et 
al， 1993)， l-[(2-hydroxy-ethoxy)methyl]-6-phenylthiothymine (HEPT) 
derivatives (Tanaka et al., 1991)，calanolides (Kashman et al., 1992), oxathiin 
carboxanilide UC-38 (Rubinerk et al., 1994). Three distinct characteristics can be 
found in these non-nucleoside inhibitors (i) high specificity for the RT of HTV-1, 
(ii) preference for polyC.oligo(dG) as the template/primer (Furfine et al., 1991)， 
(iii) selective inhibition of the RNA dependent DNA polymerization function of 
HIV-1 RT (Debyser, 1992). *« 
r 
Non-nucleoside inhibitors share common mechanism of action to HFV-1 RT. 
For TIBO derivatives, nevirapine, 0 -TIB0 and C1-TIB0 were used to demonstrate 
the mechanism of action. Nevirapine binds to a hydrophobic pocket near the 
polymerization active site. It interacts with Tyr ^^ ^ and Tyr 哪 on p66 of the 
enzyme suggesting that it is a non-competitive inhibition. This leads to 
conformational change and hence inhibits catalysis, chemical reaction, product 
release and even change in the rate-limiting step during steady state catalysis. It 
slows down the rate of chemical reaction catalyzed by RT (Spence et al.,l995). 
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However, the similarity in action may also cause development of resistance. 
Genetic analysis shows that amino acid mutation at residue located in 97-108 
residue andA)r 181 residue were commonly found upon prolonged drug treatment. 
Also, different class of compound show difference in amino acid change (Emini, 
1996). 
1.3.2 HIV integrase OB[IV IN) 
HIV integrase is a relatively new target for AIDS therapy. It is an enzyme that 
catalyses the integration of the viral DNA into host DNA. The enzyme has 288 
amino acid residues that fold into three domains; the N- terminal, C- terminal 
domain and the core domain (Andrake et al., 1996). The core domain contains two 
aspartates and one glutamate which are essential for catalysis. Moreover, Mg2+ or 
Mn2+ are also essential for catalytic activity (Khan et al., 1991). HIV E^ catalyzes 
two reactions known as processing and strand transfer. The viral DNA is firstly 
cleaved by HFV JN at a CA dinucleotide at 3'-end to leave the two-nucleotide 
overhanging (Roth et al., 1989). This step is known as processing. Then protein-•• 
DNA complex is transported into nucleus. The host DNA is cut to leave a 
5'overhang of five bases and the 3'ends of the viral DNA are covalently linked to 
the 5'-end of host DNA (Engelman et al., 1991). Finally, the 5-base gap between 
5'end of viral DNA and the 3'-end of host DNA is filled in by host cell enzymes 
(Thomaser al., 1997). 
It was found that compounds with multiple aromatic rings and aryl 
orthohydroxylation are required for HIV n^ inhibition. Compounds include 
flavones, caffeic acid phenylethyl ester (CAPE), arctingenin-based compounds 
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and bis-catechols. These inhibitors may be described in general as consisting of 
two aryl units, at least one of which contains the 1,2-dihydroxy pattern, separated 
by an appropriate linker segment (Zhao et al, 1997) . These compounds do not 
bind DNA (Fesen et al., 1994). However, little is known about the mechanism of 
inhibition by these compounds. Compounds that exhibit inhibition on HIV 
integrase are shown in Table 1.1. 
Table 1.1 HIV integrase inhibitors 
Group of Name of IC50 ( _ ) Reference 
Compounds Compounds 
Flavones Quercetin 23.6 士 6.6& 13.6 土 3.4^ Fesen et al，1994 
Baicalein i .2^ 4.3^ Fesen et al, 1994 
Bis- catechol a-conidendrol 0.5^ n.d Lafemina etal, 1995 
P- conidendrol 0.5^ n.d Lafeminagra/., 1995 
CAPE 155' 65d Fesen etal., 1994 
"a" is the IC50 of cleavage, "b" is IC50 of integration, "c" is the IC50 with Mg2+. 
"d" istheIC5owithMn2+. 
1.3.3 HIV protease (mW PR) 
Afte'r HIV vims enters the host and undergo reverse transcription and 
integration, the vims expresses the useful protein and then releases the matured 
vims. fflV protease plays an important role in producing mature virus. It is an 
asparatyl protease with two identical 99 amino acid monomers. The enzyme is a 
homodimer and each subunit contains a single active site in each monomer. Two 
polyproteins are produced during translation. One is called p55 gag and the other 
one is called pl60 gag-pol. The enzyme cleaves these proteins via hydrolysis of a 
peptide bond at the scissile sites. The structural proteins are produced after 
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cleavage by HFV PR. 
There are three basic design strategies for inhibitors of HIV PR being 
described, i) peptidomimetic, ii) C2-symmetry and iii) non-peptide cyclic ureas 
(Markowitzer al., 1996). 
The specific cleavage site for HIV protease, Phe-Pro or Tyr-Pro not 
hydrolyzed by mammalian endopeptidases, was targeted to design selective 
inhibitors for HTV protease. Peptidomimetic method is based on transition state 
mimetics which include hydroxyethylene isosteres，phosphinic acid, reduced 
amide and hydroxyethylamine mimetics. The peptide is based on the pol fragment 
Leui65-Ilei69 containing transition state moiety Phev/[CH(OH)CH2N]Pro in place 
of the Phei67-Prc)i68. it was found that hydroxyethylamine transition-state 
mimetics incorporating an analog of the amide bond of Phe-Pro are very potent 
and highly selective inhibitors of HIV protease (Roberts, et al., 1990). However, 
these inhibitors exhibited poor in vivo pharmacological properties such as poor 
oral absorption, poor stability and rapid metabolism. It was demonstrated by 
crystallography that HW PR exists as a symmetric homodimers. The structure of 
1^  
active site exists as C2 symmetry. Therefore, C2 symmetric inhibitors were 
designed with less peptide-like in nature. Drug discovery approaches are based on 
the screening of renin inhibitors against HTV protease and synthesis of peptide 
substrate analogs in which the scissile P l -P l ' amide bond has been replaced by 
nonhydrolyzable isostere with tetrahedral geometry. The first drug of this category 
is A-74704. It contains phenylalanine at Pl -Pl ' , valine at P2-P2' and a 
carbobenzyl group at P3-P3'. This compound binds tightly and symmetrically to 
the enzyme with a Kj at 4.5nM (Erickson et al., 1990). 
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The third group of HFV protease inhibitors are non-peptide cyclic ureas. The 
fimdamental feature of these inhibitors is the presence of cyclic urea carbonyl 
oxygen that mimics the hydrogen-bonding of a key structural water molecule. The 
water molecule accepts two hydrogen bonds from residue Ile50 and Ile50'and two 
hydrogen bonds to carbonyl oxygen of the inhibitor. The moiety of cyclic urea is 
to provide a rigid framework and conformation. Moreover, the cyclic urea oxygen 
is used as a surragate for the structural water molecule in the protease-inhibitor 
complex (Lam et al., 1994). 
1.3.4 Chemokine receptors 
Chemokine receptors were first discovered through their role in bacterial 
toxicity. Formyl peptides produced from bacteria were found to be potent 
activators of immune cells. Chemokine receptors are integral membrane 
glycoproteins with heptahelical structure composed of seven helices snaking 
through the membrane. These receptors composed of 350 amino acids with 
molecular weight of 40kDa. It is a G-protein coupled receptor. The binding of 
chemokine leads to signal transduction and a series of early events (calcium influx, 
PI turnover) and late events (chemotaxis, actin polymerization) fVaddi et al,, 
1997). 
The role of chemokine receptors on HTV infection was firstly reported in 
1996. It was found on the host cell surface critical for HIV infection. Chemokine 
receptors found on macrophage and lymphocyte are different. The macrophage 
expresses chemokine receptor CRC5 while the lymphocyte expresses CXCR4 on 
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its surface (Marshall, 1997). The specificity of this interaction determines the 
tropism of the virus for particular cell types. Macrophage tropic (M-tropic) 
requires CRC5 whereas T cell line tropic (T-tropic) requires CXCR4. The entry of 
HrV is mediated by the interaction between viral envelope glycoprotein and CD4 
receptor with one or more members of CC or CXC chemokine receptor family 
(Endres et al., 1997). Inhibition of chemokine receptor-HIV interaction is thus a 
putative new target for drug development. Only a few of these compounds were 
found to inhibit the receptor interaction. Small molecules and antibodies were 
shown to prevent chemokine receptor exhibiting HW-l coreceptor properties. 
These small molecules are short peptides. T22 ([Tyr, Lys]-polyphemusin II) is a 
synthetic peptide with 18 amino acid residues and an analogue of polyhemusin II 
isolated from the hemocyte debris of American horseshoe crabs. It was found that 
T-tropic HIV-1 infection to the cells expressing CXCR4 and CD4 was inhibited. 
T22 did not inhibit infection to the cell expressing CCR5 and CD4 (Murakami et 
al., 1997). Another small molecule is called ALX40-4C. It is a polypeptide of 9 
arginine residues stabilized by terminal protection and inclusion of D amino acids. 
It inhibited infection by T-tropic virus strains before reverse transcription with an 
IC50 of 3nM. CCR5 -dependent virus infection was not affected. ALX40-4C binds 
on CXCR4 directly based on the observation of the elimination of Ca�+ 
mobilization on T cells co-receptor directly (Doranz et al., 1997). 
Antibodies to CCR5 were found to bind specifically to the surface of CCR5-
expressing cell line. The antibodies were isolated from two individuals 
homozygous for 32-bp deletion in the gene coding for CCR5 when compared the 
serum from these individuals and those from CCR5+z+ individuals, it was found 
that antibodies bind to CCR5 receptor can inhibit infection of primary isolates of 
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fflV-1 (Ditzel etaL, 1998). 
1.3.5 Vaccine development 
Vaccination against HFV-1 is a key strategy for the control of the spread of 
AIDS. Different candidate vaccines have been designed and developed. They 
include live attenuated virus, peptide vaccine, recombinant vector vaccine and 
DNA-based vaccine. 
Peptide vaccine is based on the use of entire peptide or a short sequence of 
amino acid from an HIV protein as immunogens. The surface protein gpl60 was 
used to elicit the immune response. Recombinant canarypox vims vector 
expressing the HFV-1_ env followed by booster immunizations with a soluble 
recombinant envelope glycoprotein gpl60MN/LAi was used to induce HIV-1 
envelope specific cytotoxic T lymphocyte. The results showed that T cell line can 
be obtained from 18 out of 20 HIV-1 seronegative volunteers and CTL can be *• 
detected at least once following immunization in 7 out of 18 volunteers (Fleury et 
I 
ai,, 1996). 
Another type of vaccine is DNA-based vaccine. DNA-based vaccine has an 
ability to express antigen in vivo. There are several advantages for DNA-based 
vaccine. First of all, It can almost mimic live attenuated vaccine to produce native 
viral protein or even noninfectious viral particles in vivo. Secondly, Class I MHC-
restricted presentation of viral antigens can efficiently produce since the vaccine 
can easily access the intracellular pathway to prime the CTL arm of immune 
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system. Finally, polyvalent basis of vaccine will be used due to high mutation rate 
of the vims. DNA-based vaccine of different strain can be easily produced and 
inoculated as a mixture. It can also lower the cost of testing (Lu, 1998). Li a series 
of studies of DNA vaccination on human, three dosages (30，100，300p,g) of 
envelope vaccine were injected into 20 HIV-1 seropositive volunteers with more 
than 500 CD4+ lymphocyte/ml. The group injected by lOOfj<g dose showed increase 
in antibody response to envelope proteins and peptides. After onset of 
immunization, CTL activity increased in percent-specific lysis of envelope 
construct. Viral load measurement has not shown any clear pattem of increase or 
decrease (Bagarzzi et al, 1998). 
1.4 AIDS therapy 
1.4.1 Current status of AIDS therapy 
1.4.1.1 Drug approved by US Food and Drug Administration (FDA) 
Several drugs have been clinically approved and prescribed for AIDS patient 
since 1987. The first drug for HIV-infected and AIDS patient is Zidovidine (AZT), 
a nucleoside inhibitor of HIV reverse transcriptase. Table 1.2 summarizes the 
drugs which are currently available as anti-AIDS drugs in the markets. 
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Table 1.2 Drugs commonly prescribed for anti-AIDS therapy 
Inhibitors Generic Name Brand Manufacturer Dosage 
Name 
Nucleoside Zidovudine Retrovir Glaxo Wellcome 500-600mgyD in 
analogue (AZT) three divided 
reverse dose 
transcriptase Zalcitabine (ddC) Hivid Roche >60kg:200mg bd, 
inhibitors <60kg: 125mgbd 
didanosine (ddI) Videx Bristol-Myers 0.75mg tds 
Squibb 
Stavudine (d4T) Zerit Bristol-Myers >60kg: 40mg bd, 
Squibb <60kg:30mg bd 
Lamivudine Epivir Glaxo Wellcome 150mgbd 
(3TC) 
Non- ‘ , -^^  ^ Nevirapine ^ ^fuV? Viramune . Roxane ^ ‘ 200mg bd -
nucleoside^ )f ^ ^ ^ ^ f ^ f . ^ J Laboraties S l ^ . ^ ^ f 
reverse ：：： ： Delavirdine j% Rescriptor Pharmacia & , 400mg tds^^"' 
transcriptase � / ¥ ! 螺 、 " ^ Upjohn ^ ¾ ^ - " - - “ ’ ： 
inhibitor&Jil w � . : ¾ ¾ . . . . . .;^ ‘“ ‘ . . . � 
Protease Saquinavir Invirase Roche 600mg tds 
Inhibitors Rjtanovir Norvir Abbott 600mg tds 
Laboratories 
Lndinavir Crixivan Merck Sharp & 800mg Q8h 
Dohme 
Nelfmavir Viracept Agouron 250mg tds 




The side effects of nucleoside analogue reverse transcriptase inhibitors 
include nausea, diarrhea, headache, fatigue and musculoskeletal pain. Non-
nucleoside reverse transcriptase inhibitors have less severe side effects than 
nucleoside analogues. The main side effect is skin rash. The side effects of 
protease inhibitors include gastrointestinal problems, kidney stones, diarrhea, 
nausea and vomiting. 
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1.4.1.2 Combination therapy 
In recent years, combination therapy is highly recommended for AIDS 
treatment partly due to the problem of drug resistance of HrV and the discovery of 
more potent, less toxic HIV inhibitors. Combination therapy is based on the use of 
two or more drugs simultaneously. Most current recommendation includes using 
two nucleoside inhibitors and one protease inhibitor (Chopra et al., 1997). 
Effectiveness is measured by CD4 T cells rise, clinical outcome of slowed disease 
progression as well as a fall in plasma HIV RNA load (Wong et aL, 1998). 
Most of the combination regiment of drugs are under different phases of 
clinical trial. In a double-blind study (ACGT 229) involving 302 patients with a 
history of extensive AZT treatment, one of three therapeutic regiments: AZT and 
ddC; AZT, saquinavir and AZT, ddC and saquinavir were tested. After 24 weeks, 
the three-drug regiment were more effective in increasing CD4 T cell count (40 to 
50 cell increase) and decreasing viral load (0.5 log decline in HW RNA) (Chopra 
ef aL, 1997). Apart from combination of AZT, ddC and saquinavir, combination *• 
with 3TC and AZT, including non-nucleoside reverse transcriptase inhibitor and 
r 
various protease inhibitors were under clinical trial and preliminary results 
showed that HIV RNA levels reduced dramatically with some 3TC combination 
regimens (Perry et al, 1997). These results of clinical trial showed the 
effectiveness of combination therapy. 
1.4.1.3 Vaccine development 
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Although strong evidence showed that the development of vaccine is one of 
the effective way against HIV infection, the progress of development of HIV 
vaccine is slow due to several reasons, i) a concem of safety in using live attenuate 
virus vaccine, ii) presence of antibodies may not be crucial factor since the actual 
correlation of antibodies to the protection against HIV are unknown, iii) lack of an 
ideal animal model, iv) multiple HIV-clades (genetic subtypes) were found, v) 
mucosal immunity may be difficult to induce, vi) peptide has been proved to be 
poor immunogens requiring substantial doses to elicit even low-affinity antibodies. 
At present, DNA-based candidate vaccine expressing HTV env or HIV gag, pol 
and em have entered phase I trials (Johnston, 1997). 
1.4.2 Alternative treatment 
Chinese medicine, acupuncture, diet therapy and herbal medicine have been 
reported have beneficial effects in AIDS therapy or attenuate the development of 
AIDS from HIV-positive patients. Chinese medicine emphasizes on the holistic 
approach and always pay attention to the patient's entire body. Herbs used in 
China for immunomodulation can be classified into three categories. The first 
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group of herbs is to enhance the immune system. The second group is to inhibit 
the immune system and the third one has a non-specific adaptogenic effect (Zhang 
et al, 1995). Moreover, many plant extracts were reported to have anti-HIV 
activities. Some of them have inhibitory activities on HW reverse transcriptase 
and HIV protease (Chang et al., 1988; Xu et al, 1996). Furthermore, some natural 
products which are shown to have anti-HW activities were isolated and their 
structures were elucidated. The herbal medicine is thus considered to be rich 
sources for inhibitors targeted towards HIV replication. 
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1.5 Objective ofMy Project 
The objective of my project is to isolate and characterize active components 
from tradition Chinese medicine (TCM) for inhibition offflV-1 RT and HIV PR. 
The first stage of my project is to screen for HTV-RT inhibitory activities from 
crude extract of TCM. The next stage of my project is to further fractionate and 
characterize the most potent extract identified from stage one using different 
chromatographic strategies. Similar strategy was also adopted for the screening of 
crude extracts on inhibition of HIV protease. 
r 
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Chapter 2 Screening of traditional Chinese medicinal (TCM) plants for 
HIV reverse transcriptase inhibition 
2.1 Introduction 
2.1.1 HIV reverse transcriptase structure and function 
fAJ Structure of HIVReverse Transcriptase 
HIV reverse transcriptase is a complex multifunctional protein able to 
catalyze all steps of the reverse transcription process. This enzyme is a 
heterodimer and comprises of a 66 kDa and a 51 kDa monomers. They are also 
called p66 and p51. The p66 subunit possesses the polymerase and RNase H 
activities while p51 subunit catalyzes only DNA synthesis (Litvak et al., 1996). 
The crystal structure at 3.5 A resolution showed that the dimer is asymmetric. The 
two subunits have very different conformations in spite of having the same 
sequence. Portions of pol domain and catalytic site of RT is structurally similar to 
Klenow fragment (Kohlstaedt et al, 1992). 
The p66 subunit is folded into five separate subdomains, the RNase H 
domain and four subdomains of the pol domain. The subdomains were named as 
"fingers", "palm" and "thumb". The fourth pol subdomain lies between the rest of 
the pol and the RNase H domain, leading it to be called the "connection" 
(Kohlstaedt et al, 1992). HIV-l RNase H is a protein that have five-stranded p 
sheet and flanked by an asymmetric distribution of four a-helices (Litvak et al., 
1996). The crystal structure shows that two divalent cations bind to the active site 
of the protein. A short polypeptide loop contains the invariant His^^^ lies close to 
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the two divalent metal ions at the enzyme's catalytic center and could be involved 
in the RNase H activity (Kohlstaedt, 1992). There are four conserved amino acids, 
three are aspartic acids and one is glutamic acid (Litvak et al., 1996). The isolated 
RNase H is disordered in the crystal but it is ordered in the heterodimer and 
interact with the thumb of p51. Moreover, the expression of RNase H doesn't 
show any activity. It is because most of primer-template binding site is provided 
by the pol domain of p66 as well as by the thumb of p51 (Kohlstaedt, 1992). 
p51 subunit has the same sequence but have different conformation to p66. 
Five p strands of the palm domain hydrogen bond to the four P strands at the base 
of the thumb which in tum hydrogen bond to the connection P sheet is partly 
unraveled in the p51 subunit. It has no cleft and conserved residue that is involved 
in catalysis. The finger moves toward palm and the thumb further from the finger 
and palm domains. The tertiary structures of the four corresponding subdomains 
are largely the same in the two subunits. However, the relative position and the 
interdomain packing contacts of connection subdomain are different (Kohlstaedt, 
1992). 
r 
Amino acid sequences ^^^KLVGKL pC)i6KLLR^^^ o f f f lV RT are conserved 
in several nucleotide polymerizing enzymes. It was identified as an element of 
nucleic acid binding apparatus. It's structure is part of helix-tum-helix lies within 
thumb region. Molecular modelling studies suggest that the motif acts as a kind of 
"helix clamp,，in the p66 and p51 subunits (Hermann, 1994). 
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(C) The Process of Reverse Transcription 
The function of HrV RT can be divided into two steps. The first one is 
initiation and the second one is elongation. The initiation of reverse transcription 
is binding of tRNA onto the viral RNA. The cellular tRNA has been specifically 
packed into the virion. tRNA was selected by viral encoded protein which may be 
nucleic acid binding protein encoded in the viral genome. tRNA^^® 3 [^  used as 
primer. It binds on a sequence in the viral RNA called primer binding site Q)bs) 
which is near the 5' end of the genome (Litvak et al., 1996). 
The second step is elongation. Once the tRNA^^^ ^  binds on pbs, RT starts the 
synthesis of minus-strand DNA which copying the region of U5 and R. This 
fragment is called "strong-stop" cDNA. RNase H then removes the viral RNA so 
the "strong-strand" cDNA exposed. The cDNA is then translocated to 3，end and 
continues to synthesize the minus-strand DNA. After the complete synthesis of 
minus-strand DNA, RNase H then removes that original RNA genome except a 
region called polypurine tract (PPT). The 3'-OH will serve as the primer of plus-
DNA synthesis. The minus-DNA is also named U3-R-U5. At this time, tRNA is 
still linked on it. The tRNA is removed by RNase H once pbs of plus-strand DNA 
synthesized. Second strand transfer takes place once tRNA was removed and pbs 
of plus-strand DNA synthesized. 3' end of plus-strand strong stop-DNA hybridize 
to the pbs of minus- strand DNA which located at the 3' end of the DNA. After 
this, DNA plus- and minus- strand synthesis starts. Each newly synthesized 
double-stranded DNA contains 2 long terminal repeats (LTR) corresponds to U3-
R-U5 regions. However, the DNA product differs in length from original RNA 
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^ 
because it contains U3-R-U5 region. The double-stranded DNA is called proviral 
DNA and is ready for integrated into host genome (Litvak et al., 1996). 
2.1.2 Natural products against HIV RT 
Natural products were shown to be effective in inhibiting HIV RT. A diverse 
group of compounds were found to inhibit HIV RT such as aliphatic ketones and 
aldehydes, terpenoids, alkaloids, coumarin derivatives, flavanoids, xanthone, 
flavone-xanthone C-glucoside，hypericin, tannins, polysaccharide and protein p^g 
etal., 1997). 
Polysaccharides were found to have anti-HIV activities. Most of them are 
sulphated polysaccharides such as heparin and dextran sulphate. These 
compounds were found to inhibit HP/ replication in vitro by blocking the 
adsorption of HIV onto cells (Wright, 1995). Polysaccharide is isolated from 
Chinese medicinal herbs such as Viola yedoensis. The compound found was a 
high molecular weight sulphonated carbohydrate polymer with the molecular 
** 
weight between 10000 to 15000 0sfgan et al., 1988). Sulfated polysaccharide 
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having inhibition to HIV replication was found in Prunella vulgaris which was 
named Prunellin. The molecular weight was about 10 kDa (Tabba et al., 1989). 
Flavanoid is another group of natural products reported to be potent 
inhibitors of HW RT. Baicalein, quercetin, auercetagetin and myricetin were 
found to be potent inhibitor of HIV RT. In the presence of 2p-g/ml of quercetin, 
myricetin, quercetagetin and baicalein, the inhibition to HIV RT was 100%, 100%, 
90%, 70% respectively (Ono et al., 1990). Flavanoid can be divided into three 
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groups including flavan, flavone and flavanones. Flavans were more effective than 
flavone and flavanones in inhibition ofHIV-1 or HYV-2 infection (Mahmood et al., 
1993). Biflavanoids isolated from Rhus succedanea and Garcinia multiflorawere 
also showed inhibition of HIV-RT. Eleven biflavanoids were isolated and found 
that hinokinflavone and volkensiflavone inhibited HTV RT at an IC50 of 65^iM. 
Moreover, morelloflavone exhibited potent inhibitory activities at an EC50 of 
6.9^iM in the whole cell assay (Lin et al., 1997). 
Tannins are commonly found in plant kingdom. Several studies showed that 
tannins are potent in inhibiting HIV replication and RW RT. Tannins like 
Shephagenin A and B which were isolated from Shepherdia argentea was found 
to inhibit m V RT with an IC50 of 4.9 X 10'^ M and 7.4X10"^ M respectively. 
These two compounds contain a gluconic core (Yoshida et al., 1996). Sanguiin H-
11，punicalin and punicacortein C inhibited KW RT with an IC50 of 20, 8 and 
5^iM respectively. Punicalin and punicacortein C contain a gallayl moiety. 
Moreover, tannins also showed inhibition of HrV replication by inhibiting both 
the cytopathic effect and the expression of HIV antigen in human lymphotropic 
virus type l(HTLV-l)-positive MT-4 cells. Eighty seven chemically defined as 
tannins and related compounds were used and several compounds such as 
nobotannin B，camelliin B, nobotarmin C, trapanin B，showed anti-HFV activities 
at EC50 values between 2 to 5^ig/ml and CC50 between 30 to 75^ig/ml Q^akashima 
et aL, 1992). Furthermore, tannins had the ability to block the binding of 
recombinant HIV coat protein gpl20. Seven tannins were tested and five of them 
including chebulinic acid and punicalin completely inhibited the binding of aCD4 
(Weaver etal., 1992). 
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2.1.3 Inhibitory activities from plant extracts 
Crude plant extracts from different places were also found to be effective in 
inhibiting HFV RT. Extracts of forty one folk medicine used in Egypt were 
screened and six of them showed significant inhibitory activity with an IC50^ 
50ng/ml. They included extracts from Phyllanthus amblica, Quercus pedunculata, 
Rumexcypruis, Terminalia bellerica, Terminalia chebula and Terminalia horrida. 
Phyllanthus emhlica showed potent inhibitory activity to HrV RT with an IC50 of 
9^ig/ml and lO^g/ml in methanol and water extract respectively (El Mekkawy et 
al., 1995). Moreover, anti-HIV activities are also found in traditional Chinese 
medicinal herbs. Twenty-seven medicinal herbs reputed in ancient Chinese 
folklore to have anti-infective properties were extracted by boiling under reflux. 
The extract was tested for inhibitory activity against HrV in the H9 cell line. 
Eleven of twenty-seven extracts were found to be active. Viola yedoensis was 
chosen for detailed study because it achieved 97-100% inhibition of the growth of 
HIV in vitro at the concentration non-toxic to the host H9 cell. The extract did not 
inactivate extracellular HIV or inhibit the growth of herpes simplex, polio or 
vesicular stomatitis virus (Chang et al., 1988). 
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2.2 Materials and methods 
2.2.1 Materials 
Thirteen dried medicinal herbs used in this project were bought in local herb 
shop. The crude extract of these herbs were previously shown to be effective in 
inhibiting HP/ replication (Chang et al, 1988). The photographs of these herbs 
are shown in Appendix 1. 
Tabte 2.1 Experimental herbs 
Chinese Name Scientific Name Part ofPlant 
川貝 Fritillaria cirrhosa Bulb 
野菊花 Chrysanthemum indicum Flower 
黃蓮 CopHschinensis Root 
紅紫草 Lithospermwnerythrorhizon Stem 
紫花地 丁 Viola yedoensis Leaves 
烤棋菊 Chrysanthemummoriforliwn Stem 
夏枯草 PnmeUamdgaris Flower 
牛等子 Arctiun lappa L Seed 
貫仲 Woodwardia unigemmata Bark 
苦參 Sophoraflavescens Stem 
穿心蓮 Andrographis paniculata Grass 
r 
金銀花 Lonicera japonica Leaves/Shoots 
千里光 Senecio scandens Stem 
Non-radioactive assay kit for HW reverse transcriptase (Cat No. 11468120), 
sucrose and proteinase K were obtained from Boehringer Mannheim. Agarose, 
Superscript II and oligonucleotide primers were obtained from Gibco BRL. D+ 
mamiose was obtained from Aldrich, L+ rhamnose was obtained from Hopkin & 
Williams Ltd. D-ribose was obtained from Lancaster. 
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Trypsin, 2-p^-Morpholino]ethanesulfonic acid (MES), a-, p-glucosidase, 
sodium periodiate, polyvinylpyrrolidone, Folin-Ciocalteu reagent, D-arabinose, a-
D+ fucose, D+ galactose, D+ galactosamine, N- acetyl D-galactosamine, glucose, 
D+ glucosamine, D+ raffinose, a-D-talose, xylose, D-galactouronic acid, 
polygalacturonic acid, mannosamine, a-D+- melbiose, oleanolic acid, ursolic acid, 
oleandrin, baicalein,(+)-catechin, tannic acid were obtained from Sigma. 
Polyamide resin MN Polyamide CC6 was obtained from Mecherey-Nagel. 
Poly-Prep Chromatography Column, Econo-column and microtiter plate reader 
(Model 3550) were obtained from Bio-Rad. Sephadex LH-20, ClO/20 Column, 
Gradifrac chromatographic system including chart recorder REC 102, Readifrac 
and 100bps DNA ladder were obtained from Pharmacia. Vydac Cig 
proteiny'peptide reverse phase column 218TP was obtained from Separation Group. 
HPLC system which includes the 600S controller, 486 tunable absorbance 
detector were obtained from Waters. 
Dialyzing membrane (3500 MWCO) was obtained from Spectrum. Methanol 
(Anal grade) and methanol (HiPerSolv) was obtained from BDH. Nunc-Lmnuno 
Wash 8 was obtained from Nunc. TLC plastic sheets silica gel 60 F254 was 
obtained from Merck. The 0.22 micron filter was obtained from Micron 
Separation tic. 
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2.2.2 Extraction methods 
2.2.2.1 Methanol extraction 
Two grams of dried herbs were cut into small pieces and were soaked into 30 
ml of methanol for 24 hours at 4 °C. The herbal extract was then filtered through 
Whatman Paper No. 1 to remove the insoluble material. The extract was then 
dried by evaporation and kept at 4°C until use. 
2.2.2.2 Hot water extraction 
Two grams of dried herbs were cut into small pieces and were soaked in 
50ml of double-distilled water and boiled under reflux for 2 hours. The extract 
was then filtered through Whatman Paper No.l. The filtrate was dialyzed with 2 
litre of double distilled water for 24 hours at 4°C with 3500 MWCO dialyzing 
membrane. The extract was frozen and lyophilized. The lyophilized extract was 
kept at -20�C. 
2.2.2.3 Preparation ofPrunella vulgaris extract 
Ten grams of dried Prunella valgaris was soaked into 250 ml of double 
distilled water and boiled under reflux for 2 hours. The extract was filtered 
through Whatman Paper No.l and then dialyzed in 6 litre double distilled water at 
4 °C with 3500 MWCO dialyzing membrane. The extract was then frozen and 
lyophilized. The lyophilized extract was kept at -20°C. 
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2.2.3 HIV reverse transcriptase assay 
The procedure for HFV reverse transcriptase assay was carried out according 
to the instructions provided by Boehringer Mannheim. Solutions and kit 
components were prepared according to the instruction manual as supplied in the 
assay kit. The kit was stored at -20°C. The washing buffer, ABST substrate buffer 
and anti-DIG-peroxidase were stored at 4°C. 
The HTV reverse transcriptase solution was made by 20 fold dilution. The 
final concentration of HIV RT was 2ng/well. The reaction was performed in 
microtiter plate which was precoated with streptavidin and placed on strip frame 
provided by the kit. Total reaction volume was 60pi containing 20p,l of HIV 
reverse transcriptase, 20^il of substrate solution mix containing DIG-dUTP, biotin-
dUTP and dTTP in 50mM Tris-HCl, pH7.8, template (template/primer hybrid 
poly (A) . oligo (dT)i5) and 20p,l of herbal extract being tested. For positive 
control, a mixture of 20p,l of HFV reverse transcriptase, 20p,l of nucleotide 
substrate and 20^il oflysis buffer (50mM Tris, 80mM KC1, 2.5mM DTT, 0.75mM 
EDTA and 0.5% Triton X-100) were added together. For negative control, 20^il of 
nucleotide substrate and 40fil of lysis buffer, no HTV RT was added. The 
microtiter plates were covered with self-adhesive cover foils provided with the kit 
and incubated at 37°C. 
After one hour of incubation, the reaction mixture was washed five times 
each with 250p,l of washing buffer by the use ofNunc-Dnmuno Wash 8 each time. 
Each well should be completely dried at the final wash. Two hundred microliter of 
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anti-DIG-POD which was diluted 100 fold from the stock solution was added into 
each well. The plate was covered with self-adhesive cover foils and incubated at 
37�C for 1 hour. 
The anti-DIG-POD solution was removed by washing the plate with 250p,l 
washing buffer for 5 times. The well should be completely dried at the final wash. 
After washing，200^il of ABST substrate in substrate buffer (sodium perborate and 
citric acidy' phosphate buffer) was added in each well and allowed for incubation at 
room temperature for half an hour. Absorbance of each well was determined by 
using microtiter plate reader with wavelength at 405 nm and reference wavelength 
at 490 nm. 
2.2.4 Characterization of active components in extract of Prunella vulgaris 
2.2.4.1 Protease digestion 
An amount of 89.1^g of Prunella vulgaris extract was digested with lO^g of 
either trypsin or proteinase K in a total reaction volume of 150^.1 at 37°C for 2 
hours. 'The reaction was stopped by boiling for 20 min. 
2.2.4.2 Glucosidase digestion 
A) a-Glucosidase Digestion 
The procedure for glucosidase digestion was performed according to Collins 
et aL (1997). An amount of 81^ig of Prunella vulgaris water extract was dissolved 
in 70^tl of a-glucosidase buffer (50mM 2-pSf-Morpholino]ethanesulfonic acid 
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(MES), pH 6.5) to 40p,l of a-glucosidase buffer and lOp.1 of a-glucosidase with 
stock at 200U/ml were added. After vortex and incubation at 37°C for 2 hours, the 
reaction was stopped by boiling for 15 min. 
B) p-Glucosidase Digestion 
An amount of 81 [ig of Prunella vulgaris water extract was dissolved in 70^1 
of p_glucosidase buffer (50mM sodium acetate, pH 5.5) and mix with 30^1 of p_ 
glucosidase buffer and 20^il of lOOU/ml P-glucosidase. The reaction was 
incubated at 37°C for 2 hours and was stopped by boiling for 15 min. 
2.2.4.3 Ethanol precipitation 
The procedure of ethanol precipitation was modified according to Yao et al. 
(1992). Twenty-six micrograms of Prunella vulgaris extract was dissolved in 2ml 
of wafer and then 8ml of absolute ethanol was added to a final concentration of 
80%. The mixture was allowed to stand overnight at 4°C. the precipitate was 
collected after centrifligation at 12000g for 20 min. Both the pellet and 
supernatant were collected and dried by speedvac and kept at 4°C. 
2.2.4.4 Sodium periodate oxidization 
The procedure for sodium periodate oxidization of polysaccharide was 
modified according to De Ruiter et al. (1994). Five milligrams of Prunella 
vulgaris extract was dissolved in 2ml of 0.02M NaIO4 and incubated in the dark at 
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room temperature for 12 hours. The treated extract was then dialyzed against 1 
liter ofdouble distilled water ovemight at 4°C and then lyophilized. 
2.2.4.5 Polyvinylpyrrolidone (PVP) Precipitatioin 
The procedure for polyvinylpyrrolidone was performed according to Tan et al. 
(1991). Two milligrams of Prunella vulgaris crude extract was dissolved in 1ml 
double distilled water and 500^il of which was boiled for 15 min followed by the 
addition of 500^il 5% ofPVP prepared in double distilled water. The mixture was 
vortexed vigorously for 5 min. 
2.2.4.6 Polyamide resin binding 
Polyamide resin column was prepared according to Wall et al. (1969). 
Polyamide resin (MN Polyamide CC6) with particle size 0.1-0.3mm was soaked 
in double distilled water ovemight. The resin was packed into a Poly-Prep 
Chromatography Column. Three milligrams of extract was dissolved in double 
distilled water and applied to the column. The column was then eluted with 10ml 
of double distilled water, 10 ml of 50% methanol and 30ml of 100% methanol. 
The combined methanol eluate was dried by evaporation. The column was then 
washed with 10ml of water and eluted with 30ml of O.lM NaOH. The pH of 
NaOH eluate was adjusted to 5.6 with concentrated HC1. After neutralization, the 
eluate was dialyzed against 2 litre of double distilled water for 5-8 hours. The 
eluate was then lyophilized. 
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2.2.5 Purification ofPrunella vulgaris extract 
2.2.5.1 Polyamide resin column chromatography 
Polyamide resin was soaked with double distilled water ovemight and then 
packed into an Econo-column (2 X lOcm). An amount of 40mg of Prunella 
vylgaris extract dissolved in autoclaved double distilled water was then loaded to 
the column. The column was first eluted by 20ml of double distilled water, 20ml 
of 50% methanol and 60ml of 100% methanol. The eluate was discarded and the 
column was equilibrated with 20ml of double distilled water followed by 60ml of 
O.lM ofNaOH. The pH ofNaOH eluate was adjusted to 5.6 by adding HC1. After 
dialysis against twelve litre of double distilled water ovemight at 4°C (MWCO 
3500)，the eluate was frozen and dried by freeze dryer. Lyophilized extract was 
weighed and was kept at 4°C. 
2.2.5.2 Sephadex LH-20 chromatography 
The purification procedure was according to Lu et al., (1997). Spehadex LH-
20 was soaked in 20% ethanol ovemight and then packed in ClO/20 column 
I 
connected to Gradifrac chromatographic system. The column was then washed 
with 3 gel volumes of double distilled water. Forty milligrams ofPrunella extracts 
prepared from polyamide resin chromatography was re-dissolved in autoclaved 
nanopure water and then loaded to the column. The column was eluted with 
methanol increasing from 0% to 100% for 10 min at a flow rate of 2ml/min. One 
ml per fraction was collected. The eluate was monitored at 280nm. Identifable 
peak fractions were recorded by a chart recorder (REC 102) at chart speed 
5mm/min and peak input at 50mV. The collected fractions were then dried by 
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speedvac. The dried eluate was weighted and dissolved in 1ml autoclaved 
nanopure water. Twenty microliter of each fraction were taken for RT assay to 
monitor the inhibitory activity. 
2.2.5.3 Reverse phase HPLC purification 
The HPLC purification was done according to Lu et al. (1997). Cig column 
(Protein/peptide Reverse Phase Column 218TP) was used. Solvent A was 0.1% 
acetic acid using nanopure water and solvent B was 100% methanol with 0.1% 
acetic acid. Solvent A was degassed by ultrasound for 30 minutes before use. The 
column was equilibrated by solvent B overnight at a flow rate at O.lml/min 
followed by equilibration in solvent A at a flow rate of O.lmlAnin. 
The active fraction from Sephadex LH-20 chromatography was collected, 
dried by speedvac and resuspended in 1ml of autoclaved nanopure water. After 
centrifugation at 13000rpm for 10 minutes to remove insoluble materials, the 
supernatant was then filtered through a 0.22 micron filter. Fifty microliter of the 
fraction was loaded to the Cig column equipped with Waters HPLC system (600S 
Controller). The extract was eluted with a methanol gradient as shown in the 
following table 
Time (min) 0 40 45 50 
SolventA(%) m"""50 50 i00~~ 
Solvent B (%) 0 50 50 0 
at a flow rate of0.6ml/min. The absorbance of eluate was monitored at 320nm for 
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the detection of phenolic compounds (486 Tunable Absorbance Detector) (Strack 
et al., 1989). Two ml per fraction were collected in a Readifrac fraction collector. 
The collected fractions were dried by speedvac, resuspended in lOOp,l double 
distilled water and 20fil of each fraction was used for HIV RT assay. 
2.2.6 Characterization of purified Prunella vulgaris extract 
2.2.6.1 Paper chromatography 
The procedure for paper chromatography was done according to Waterman et 
al. (1994). A piece of 3MM Whatman paper was cut into 20cm x 20cm in size. A 
straight line was drawn 2 cm above the bottom edge of the paper. Ten microliter 
of sample was loaded along the line with 2cm gap between each sample. The 
mobile phase contained butanol-acetic acid-double distilled water (4:1:5 v/v). Two 
hundred ml of mobile phase was added into a 500 ml separating funnel and shaken 
for 5 minutes. The mobile phase was separated into two phases and the upper 
phase in separating funnel was added into the glass tank. After saturating the glass 
tank with mobile phase for at least 30 minutes, the paper was then placed into the 
tank and run for 3 hours. The paper was taken out and the solvent front was 
r 
marked immediately. After air dried in fume hood, the paper was sprayed with 
Folin-Ciocalteu Reagent, followed by 20% Na2CO3 immediately. Afterward, the 
paper was sprayed by 5% Na2CO3 and dried by air in fame hood. The presence of 
blue colour spots is indicative of the presence of polyphenolic compounds in 
samples. 
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2.2.6.2 Acid hydrolysis 
The procedure of acid hydrolysis was done according to Lu et al (1997). Two 
hundred i^l of eluate in each purification step was mixed with 200^il of 4M HC1 to 
a final concentration o f2M HC1. The sample was then boiled at 100�C for 2 hours. 
After hydrolysis, the sample were dried by speedvac, resuspended in 200^1 of 
double distilled water. 
2.2.6.3 Thin layer chromatography 
TLC plastic sheets (20cm x 20cm) silica gel 60 F254 were used. A line was 
drawn at 2cm above the bottom edge. Ten |il of sample and 2^il of standard 
monosaccharides were spotted with 1.5cm gap from each other. The standard 
monosaccharides were D-arabinose, a - D+- fucose, D+ galactose, D+ 
galactosamine, N-acetyl D-galactosamine, Glucose, D+ glucosamine, D+ mannose, 
D+ rafFinose, L+ rhamnose, D- ribose, Sucrose, a-D-talose, Xylose, D-
galactouronic acid, polygalacturonic acid, mannosamine and a_ D+_ melbiose 
The TLC plate was eluted in a mobile phase of methanol-water-acetic acid 
(8:2:0.1 v/v). After saturating the glass tank with mobile phase for at least 30 
minutes, the TLC plate was placed into the tank. After running for 3 hours, the 
plate was taken out and the solvent front was marked immediately. The plate was 
dried by a stream of cold air and then subjected to monosaccharide detection 
according to Jork et al. (1990). Briefly, the plate was first soaked in solvent I 
(Solvent I: AgNO3 was saturated in 1ml of double distilled water, and then 200ml 
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of acetone was added. White precipitate formed was collected and dissolved in 
5ml of double distilled water and stirred to dissolve it) for 1 min. The plate was 
taken out and dried by a stream of warm air and then soaked in solvent II (2g of 
NaOH was dissolved in 2ml of double distilled water. Then 100ml of methanol 
was added and mixed) for 2 min, baked at 120°C for 2 minutes to develop the 
brownish colour for the presence of monosaccharide. The background light 
brownish colour was destained by spraying with 5% sodium thiosulphate in 50% 
ethanoL 
2.2.6.4 Other assays 
A) Polymerase Chain Reaction 
To test whether the Prunella vulgaris extract can also inhibit other polymerase 
such as Taq polymerase, PCR was performed by mixing 23p,l PCR mix which 
contained 5p,M primer 1 and primer 2 (HET-1 249 and HET-1 895 for endothelin-
1 PCR), 200^iM dNTP and IX PCR buffer(50mM KC1, lOmM Tris-Cl pH 9.3， 
1.5mM MgCl2 and 0.01% gelatin) with 2^1 cDNA. 0.2mgAnl ofpurified extract in 一 
each step was added into PCR mixture. 0.2^il of Taq polymerase was added. 29 
PCR cycles were run by using minicycler with denaturation at 98°C for 45 sec, 
annealing at 58°C for 45 sec, polymerization at 72°C for 1.5 min. 
B) Agarose Gel Electrophoresis 
15^il of PCR product mix with 3^il of 6X loading buffer (0.25% bromophenol 
blue, 40% (w/v) sucrose in water) and 1 OObp DNA ladder was used as molecular 
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size marker. 2% agarose gel was prepared by using IX TAE (0.04M Tris-acetate 
and 0.001M EDTA) as buffer with 0.5^ig/ml ethidium bromide. IX TAE was used 
as electrode buffer. Electrophoresis was run with 100V for 45 minutes. The bands 
were visualized by a transluminator (Spectroline TVC-312A) and the image was 
captured by Polaroid direct screen instant camera with Polaroid 667 film. 
2.2.7 Calculations 
Calculation of percentage inhibition is 
fAbs of control 2-Abs of control 1) - (Abs of sample - Abs of controll) X 100% 
Abs of control 2- Abs of control 1 
Where control 1 is HIV RT assay without adding enzyme. Control 2 is HIV RT 





2.3.1 Screening of herbs 
2.3.1.1 Screening of methanol extracts 
Methanol extracts of thirteen Chinese medicinal herbs were screened for 
inhibitory activities on HIV reverse transcriptase. It was found that eleven extracts 
had inhibitory activities below 30% at 0.2mg/ml including F. cirrhosa, C. indicum, 
C. moriforlium, P. vulgaris, A. lappa L, W. unigemmata, S. flavescens, A. 
paniculata, L erythrorhizon, V. yedoensis, L japonica and S. scandens. These 
extracts were considered not very effective on HTV RT inhibition. The most potent 
extract was from C. chinensis which has an inhibition of91.33% (Table 2.2). 
2.3.1.2 Screening of water extracts 
Hot water extracts were screened for inhibitory activities on HTV RT at 
concentration 0.2mgAnl. Any inhibition below 50% is regarded as not effective. 
Eight extracts had inhibitory activities below 50% including C. imdicum, W. »* 
unigemmata, S. flavescens, A. paniculata, F. cirrhosa, C. chinensis, V. yedoensis, 
I 
A. lappa L. and L japonica. Three extracts had inhibitory activities between 50-
60% including L erythrorhizon, C. moriforlium and S. scandens. Prunella 
vulgaris water extract was the most potent extract having about 95% inhibition. 
The extract of Prunella vulgaris was thus chosen for farther purification and 
characterization (Table 2.3). 
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Table 2.2 Effects of partially purified methanol extracts of Chinese medicinal 
herbs on HIV RT inhibition 
: Name % Inhibition 
Fritillaria cirrhosa (川貝) 25.86±1.65 
Chrysanthemum indicum (ff 菊 ^ ) 23.21 土 1.63 
Coptis chinensis (黃蓮） 91.33 士 2.12 
Lithospermum erythrorhizon (紅紫草) 17.07 土 5.78 
Violayedoensis (紫花地丁） 13.17±6.03 
Chrysanthemum moriforlium (榜棋菊) 25.23 土 2.37 
Prunella vulgaris (夏枯草） 27.67 土 1.65 
• Arctiunlappa L (牛等子） 22.43 ±1.02 
Woodwardia unigemmata (貫仲) 23.79 土 2.85 
Sophoraflavescens (苦參） 25.80土2.42 
Andrographispaniculata (穿心蓮) 22.86 土 0.74 
Lonicera japonica (金銀花） 17.86士6.22 
*• 
Senecio scandens (千里光） 13.54 土 5.39 
All extracts were tested at 0.2mg/ml. Values are mean 土 S.E.M. at a n=6. 
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Table 2.3 Effect of partially purified water extracts of Chinese medicinal herbs 
on fflV RT inhibition 
Name % Inhibition 
Fritillaria cirrhosa (川貝) 17.97±6.54 
Chrysanthemum indicum (野菊 ^ t ) 34.45 土 4.63 
Coptis chinensis (黃蓮） 24.09±8.37 
Lithospermum erthrorhizon (、红紫草) 46.88 ± 5.01 
Violayedoensis (紫花地丁）21.8土8.61 
Chrysanthemum moriforlium (榜棋菊) 54.83 ±5.61 
Prunella vulgaris (夏枯草 ) 9 5 . 3 6 土 0.42 
Arctiunl—aL. (牛等子）28.11±4.88 
Woodwardia unigemmata (貫仲) 36.50 土 5.85 
Sophora flavescens (苦參) 30.01±5.81 
Andrographispaniculata (穿'c^�蓬) 33.69 ± 6.38 
Lonicera japonica (金銀花）24.92 土 7.24 
Senecio scandens (千里光） 40.66 土 4.61 
t* 
Extracts were tested at concentration 0.2mg/ml. Values are means 
士 S.E.M. at a n=6. 
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2.3.2 Characterization of active components in Prunella vulgaris crude 
extract 
2.3.2.1 Protease digestion 
In order to test whether the active component is proteinous in nature and to 
remove any protein material that may interfere with the assay, the partially 
purified extracts of Prunella vulgaris was pre-treated with trypsin or proteinase K 
before assay. As shown in Table 2.4, the percentage inhibition by either trypsin or 
proteinase K pretreatment was not significantly different from the untreated 
control. It was concluded that the inhibition was not due to proteinous material in 
the extract. 
2.3.2.2 Glucosidase digestion 
The partially purified extract of Prunella vulgaris was pre-treated with a -
and p-glucosidase in order to find out whether the inhibitory activity is due to the 
presence of polysaccharide or not. The samples were treated with appropriate 
glucosidase for two hours. It was found that the pre-treatment with glucosidase did 
not moclify the inhibitory activities on HIV RT (Table 2.5). 
2.3.2.3 Ethanol precipitation 
The polysaccharide can also be precipitated in 80% of ethanol. Ethanol was 
added to the extract to 80% and after centrifugation, the pellet and supernatant 
were collected and an aliqout was used to measure inhibitory activity to HIV RT. 
It was showed that both the pellet and supernatant had similar inhibitory activity 
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(86.7% vs. 77.5% respectively)(Table 2.6). 
Table 2.4 Effect of protease digested Prunella vulgaris water extracts on HIV RT 
inhibition. 
“ Treatment % Inhibition 
No digestion 82.75 土 5.00 
Trypsin digestion 70.73 土 4.04& 
Proteinase K digestion 72.18 士 3.95^ 
The extract (0.2mg/ml) was digested by lOfig of trypsin 
and proteinase K respectively. The concentration of 
both control and protease treated extract is 0.2mg/ml. 
Values are means 士 S.E.M. with n=6. "a" means p > 




Table 2.5 Effect of glucosidase digested Prunella vulgaris water extract on HIV 
RT inhibition. 
Treatment % Inhibition 
Control 82.75 ± 5.00 
a-glucosidase digestion 82.68 士 1.02a 
P-glucosidase digestion 77.79 土 1.79^ 
Prunella extract was digested by 2U/^il of a-glucosidase 
and lU/^1 of p-glucosidase for 2 hours. The 
concentration of both control and treated extract are 
0.2mg/ml. Values are mean 土 S.E.M. with n=6. "a" 





Table 2.6 Effect of ethanol precipitation of Prunella vulgaris water extract on 
HW RT inhibition. 
Sample % Inhibition 
Prunella vulgaris crude extract 88.3 5 土 3.12 
80% ethanol precipitation Q)ellet) 86.7 土 2.68 
80% ethanol precipitation (supernatant) 77.5 土 4.02a 
Both the pellet and supematant were collected to measure the 
inhibitory activities on HIV RT. Concentration of crude and ethanol 
precipitated extract was 0.2mg/ml. Values are means 土 S.E.M. with 




2.3.2.4 Sodium periodate oxidization 
Prunella vulgaris extract was treated with sodium periodate in order to 
oxidize polysaccharides present in the extract. Inhibitory activity on HIV RT was 
measured after dialysis and lyophilization. It was found that the NaIO4 oxidized 
extract exhibited similar inhibition compared to the untreated control. (Table 2.7) 
2.3.2.5 Effect of naturally occurring chemicals on inhibition of HIV RT 
It has been known that aqueous extract of Prunella vulgaris contains 
abundant amount of polyphenolic compounds. Li order to test whether inhibition 
was due to these chemicals, the effects of baicalein, tannic acid and catechin were 
examined. All of these compounds showed various degree (Tannic acid 61.78%, 
catechin 31.38% while baicalein 40.92%) of inhibition to fflV RT at l.lmg/ml. 
The effects of tannic acid, catechin and baicalein were shown in Table 2.8. 
However, none of them reached > 90% inhibition even at high concentration. 
*• 
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Table 2.7 Effects of NaIO4 oxidized Prunella vulgaris water extract on HIV RT 
inhibition 
Sample % Inhibition 
Prunella vulgaris crude extract 91.92 土 1.67 
NaI04 treated Prunella vulgaris extract 92.78 土 2.62b 
The extract was reacted with 2M of NaIO4 in the dark for 12 
hours and it was then dialyzed and lyophilized. Concentration of 
both crude extract and NaIO4 oxidized extract is 0.2mg/ml. 
Values are means 土 S.E.M with n=4. "b" means p > 0.05 
compared to untreated control by student's t-test. 
r 
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Table 2.8 Effect of naturally occurring chemicals ^)henolic compounds) on 
inhibition ofHIV RT 
Compound % Inhibition 
Tannic acid 61.78±3.06a 
Baicalein 40.92 士 4.74^ 
Catechin 31.38i8.66a 
Tannic acid was dissolved in water with concentration l.lmg/ml. 
Catechin was dissolved in 20% methanol with concentration 
l.lmg/ml. Baicalein was dissolved in DMSO with concentration 
1.4mM. Values are mean 土 S.E.M. with n=4. "a" means p < 0.05 




2.3.2.6 Effect of removal of polyphenolic components in Prunella vulgaris 
aqueous extracts on inhibition of HIV RT 
(A) Effect of removal ofphenolic compounds by PVP 
The phenolic compounds in plants can be effectively removed by PVP 
precipitation (Tan et al., 1991). The aqueous extract was mixed and vortexed 
vigorously with PVP solution as described in the Material and Methods. It was 
found that the inhibition on HIV RT in PVP precipitated extract reduced 
drastically as compared to the untreated control. (Table 2.9a) 
(B) Polyphenols removal by polyamide resins 
Polyamide resin absorption is another method to remove phenolic 
compounds from the extract (Tan et al., 1991). Polyamide was soaked and packed 
into a column. After loading the sample, the column was eluted with different 
concentration of methanol and then with O.lM NaOH. The colour of methanol *^  
eluate and O.lM NaOH eluate are different. The colour of methanol eluate was 
light brown while that of O.lM NaOH eluate was darkish brown. Both fractions 
were tested for inhibition on HIV RT. It was found that the inhibition of methanol 
eluate on HrV RT was only 37.48% which was much lower than that of O.lM 
NaOH eluate (64.2%) (Table 2.9b). 
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Table 2.9(a) Effect of removal of phenolic compounds by PVP on HIV RT 
Sample % Inhibition 
Prunella extract 84.88 土 2.61 
Prunella extract after PVP precipitation 11.31 土 6.01 ^  
2.5% of PVP was used to precipitate the extract and the 
method was described in 2.2.4.6. The concentration of both 
crude extract and PVP treated extract was 0.2mg/mL Values 
are mean 土 S.E.M. with n=6. "a" means p < 0.05 compared to 
untreated control by student's t-test. 
Table 2.9fi) Effect of removal of phenolic compounds by polyamide resins. 
Sample % Inhibition 
Prunella extract 84.88 土 2.61 
Methanol eluate from polyamide resin 37.84 土 6.73a 
0.1M NaOH eluate from polyamide resin 64.2 土 1.62+b 
»• 
A combined fraction of 0% 50% and 100% methanol elution. 
*• The concentration of both methanol eluate and O.lM NaOH 
eluate as well as the crude extract used for HIV RT assay 
were 0.2mg/ml. Values are mean 土 S.E.M. with n=6. "a" 
means p < 0.05 compared to untreated control by student's t-
test. "b" means p < 0.05 compared to methanol eluate from 
polyamide resin. 
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2.3.3 Further purification of active components in aqueous extracts of 
Prunella vulgaris 
2.3.3.1 Absorption chromatography by polyamide resin 
The presence of inhibitory activities to HFV RT in both the methanol eluate 
and O.lM NaOH eluate indicated that the active compounds are heterogeneous. It 
was shown that the inhibitory activity was about two-third of total O.lM NaOH 
eluate on HTV RT whereas only one-third of inhibitory activity was found in 
methanol eluate. The O.lM NaOH was thus chosen for further fractionation. After 
neutralization of the eluate to pH 5.6 and dialysis, the eluate was subjected to 
further purification. 
2.3.3.2 The Sephadex LH-20 chromatography 
The O.lM NaOH eluate was then further fractionated by Sephadex LH-20 
chromatography. Figure 2.1 shows a typical chromatogram of the fractionation, 
two broad peaks (peak 1 and peak 2) were resolved monitoring at ODisonm. The 
first peak was eluted at 37% of methanol while the second peak was eluted at 80% 
methanol. The eluate collected for peak 1 was dark brown and peak 2 was light 
brown. The fraction from both peaks were pooled, dried and analyzed for HIV RT 
inhibition. The profile of inhibitory activity on HIV RT is shown in Figure 2.2. 
Both of the peaks contain approximately equal potency of inhibition on HIV RT. 
The peak 1 showed the highest inhibitory activity was chosen for further 
purification. 
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Figure 2.1 Separation of O.lM NaOH eluate of Prunella vulgaris on Sephadex 
LH-20. The concentration of O.lM NaOH eluate was 5.1mgy^ml. 
The whole system was monitored by uv absorbance at 280nm at a 
flow rate of 2ml/min. The eluate was collected by Iml/fraction. 
Peak 1 was labeled by arrow and named 1 while peak 2 was labeled 
by arrow and named 2. The sloped line was the gradient of 
methanol during elution. 
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Figure 2.2 The profile of inhibitory activities on HD/ RT from Sephadex LH-
20 chromatographic fractionation. The eluate was dried by 
speedvac and the residue was resuspended in 1ml of distilled water. 
A 10-fold diluted eluate were used to perform HIV RT assay. 
Activities peak of peak 1 and peak 2 were indicated by arrow. 
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2.3.3.3 Reverse phase high performance liquid chromatography (RP-HPLC) 
The fractions 6 and 7 were pooled from Sephadex LH-20 chromatography 
and subjected to further fractionation by reverse phase HPLC. The eluate was 
monitored at OD320nm. Two peaks could be resolved (Figure 2.3). The colour of 
eluate at retention time 6-7 min and 30-44 min were light brown. The eluate was 
collected, dried and assayed for HrV RT inhibition. The result was shown in 
Figure 2.4. Significant inhibition was found at retention times 6-7min and 30-34 
min. The one with retention time 6-7 min was collected for characterization 
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Figure2.3 RP-HPLC fractionation of aqueous extract of Pruenlla vulgaris 
from pooled active fraction from Sephadex LH-
20.Chromatography was monitored at wavelength 320 nm. 
5.3mg/ml of Sephadex LH-20 eluate was injected . The method of 
elution was described in 2.2.5.3 with flow rate at 0.6ml/min. the 
eluate was collected at 2 min/fraction. The arrow indicate the peak 
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Figure 2.4 The profile of inhibitory activities on fflV RT from RP-HPLC 
r 
fractionation. One ml of each fraction was dried by speedvac. The 
residue was then resuspended in lOO i^l distilled water and 20^1 of 
which was used for HrV RT assay. The inhibitory activity of fraction 
3 was named as 1 and fraction 18 was named as 2. 
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2.3.3.4 Recovery of extract 
Table 2.10 shows the yield and recovery of active components under several 
chromatographic steps. The weight of starting dried herb was 10.15g. After 
extraction by reflux, the weight of crude extract was 1.5453g. Eighty mg of this 
crude extract were used for polyamide resin purification and 22mg of O.lM NaOH 
eluate obtained (yield = 27.5 %). The weight of fraction 7 and 8 of Sephadex LH-
20 eluate was 5.3mg from 22mg of eluate from polyamide resin. (% yield was 
6.6%). Finally, The weight of RP-HPLC eluate was 1.7mg from 5.3mg of LH-20 
eluate and % yield was 2.2%. 
2.3.3.5 Inhibition from the extract ofvarious steps of purification 
After various steps of purification, the eluate was used to examine the 
inhibition on HTV RT. The percentage inhibition on HIV RT was summarized in 
Table 2.11. It was found that the inhibition of crude extract, O.lM NaOH eluate 
from polyamide resin, Sephadex LH-20 eluate and RP-HPLC eluate exhibit high 
percentage of inhibition on HIV RT. The percentage inhibition was between 85% 
to 95%. However, the percentage inhibition of methanol eluate from polyamide 
resin is lower which was 37.84%. 
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Table 2.10 The yield of Prunella vulgaris extracts after each purification step. 
Material Material recovered % Yield 
Prunella vulgaris dried herb 10.15g -
Herbs after reflux 1.5453g 100 
Polyamide resin purification 0.425g 27.5 
Sephadex LH-20 purification 0.028g 6.6 




Table 2.11 W:ubition of eluate from various steps of purification of Prunella 
vulgaris on HIV RT. 
Sample % Inhibition 
Crude extract 95.36 土 0.42 
O.lM NaOH eluate from polyamide 93.93 土 0.85 
resin 
Methanol eluate from polyamide resin 37.84 土 6.73 
Sephadex LH-20 eluate 85.57 土 3.47 
RP-HPLC eluate 86.05 土 1.31 
The concentration of extract used was 0.2mg/ml. Values 
are means 土 S.E.M., n=6. 
r 
61 
2.3.4 Characterization of Purified Aqueous Extract of Prunella vulgaris 
2.3.4.1 Paper chromatography 
Paper chromatography was used to detect the presence of phenolic 
compounds under each step of purification. Crude extract, O.lM NaOH eluate from 
polyamide resin, fractions 7 and 8 of Sephadex LH-20 eluate and fraction 3 of RP-
HPLC eluate which were obtained from chromatographic purification as described 
above were used for paper chromatography. Samples were loaded on 3MM paper 
(20cm X 20cm) and chromatographed in a solvent system containing butanol, 
acetic acid and water (4:5:1 v/v/v) for 2.5 hours. Phenolic compounds was detected 
by Foiln-Ciocaltue Reagent. A dark blue spot with Rf 0.48 was found in the lane 
with crude extract. However, this blue spot disappeared in other samples. On the 
other hand, a blue spot having a Rf value of 0.266 was found in O.lM NaOH eluate, 
Sephadex LH-20 eluate but not in RP-HPLC eluate (Figure 2.5). 
2.3.4.2 Dose response curve 
»• 
The concentration of extract was started from 0.3mgAnl and diluted 10-fold. 
The lowest concentration in each sample is 0.0003 mgy'ml. It was found that these 
purified extracts exhibited similar dose response curves. The ICgo of Prunella 
vulgaris crude extract, O.lM NaOH eluate, Sephadex LH-20 fraction 6 and RP-
HPLC fraction 3 was O.lmg/ml, 0.055mg/ml, 0.15mgAnl and 0.15mgAnl 
respectively (Figure 2.6 a-d). 
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Figure 2.5 Paper chromatography for polyphenoUc compounds. lO i^l of san^)le was 
loaded on the paper. The methods of paper chromatogrsqshy was 
described in 2.2.6.1. After colour development with FoUn-Ciocaltue 
reagent to detect the phenoUc compounds, blue smear developed. The 
blue spot was indicated by arrow. Lane 1 is crude extract. Lane 2 is O.lM 
NaOH eluate from polyamide resin. Lane 3 is fraction 6 of Sephadex 
LH-20 and hne 4 is fraction 3 ofRP-HPLC. 
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Figure2.6(a) Dose response curve of crude extract of Prunella 
vulgaris on HIV RT inhibition. The concentration of 
extract used is from 0.00003 mg/ml to 0.3mg/ml. Values 
are means 土 S.E.M with n=6. 
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Figure 2.6(b) Dose response curve of 0. lM NaOH eluate from polyamide 
. resin on IflV RT inhibition. Concentration of the eluate 
used is from 0.00003 mg/ml to 0.3mgAnl with 10 fold 
dilution in each concentration. Values are means 土 S.EM 
with n=6. 
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Figure 2.6 (c) Dose response curve of Sephadex LH-20 fraction 6 on 
HTV RT inhibition. Concentration of the eluate used is 
‘ from 0.00003 mg/ml to 0.3mgAnl with 10 fold dilution 
in each concentration. Values are means 土 S.E.M with 
n=4. 
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Figure 2.6(d) Dose response curve of O.lM RP-HPLC fraction 3 on 
HIV RT inhibition. Concentration of the eluate used is 
‘ from 0.00003 mg/ml to 0.3mgAnl with 10 fold dilution 
in each concentration. Values are means 土 S.E.M with 
n=6. 
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2.3.4.3 Acid hydrolysis of purified extract 
It has been reported that the extracts of Prunella vulgaris contained a sugar 
sulfate having HTV RT inhibitory activity. The purified extracts were therefore 
treated by acid hydrolysis to remove the glucoside moiety to test whether it would 
affect HD/ RT inhibitory activity. The acid hydrolysis was done on samples 
including O.lM NaOH eluate from polyamide resin, eluate ofSephadex LH-20 and 
RP-HPLC. The result is shown in Table 2.12 . It was found that the inhibition of 
acid hydrolyzed extracts were similar to the non-acid hydrolyzed controls. The 
result from paper chromatography indicated that the non-hydrolyzed extract was 
similar to the result described in 2.3.3.4. The hydrolyzed extract gave a blue smear 
as well. However, several differences can be found. First of all, the extent of the 
smear ofhydrolyzed sample were significantly longer than the non-acid hydrolyzed 
control. Secondly, the colour intensity is different. The colour of non-hydrolyzed 
extracts were more intense than the hydrolyzed one. Finally, the blue spot (Rf = 
0.266) .which was mentioned in 2.3.3.4 cannot be found in hydrolyzed extract 
(Figure;2.7). 
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Table 2.12 Effect of acid hydrolysis of Prunella vulgaris on HTV RT inhibition 
Sample % Inhibition 
Control Acid Hydrolysis 
O.lM NaOH polyamide resin 93.93 士 0.85 94.28 土 1.47& 
eluate 
Sephadex LH-20 eluate 85.57 土 3.47 86.41 土 2.88& 
HPLC eluate 86.05 土 1.31 87.05 土 0.65" 
2M of HC1 was added into 200^1 of extract and hydrolyed for 2 
hours at 100�C. The hydrolyzed extract was dried by speedvac and 
then resuspended in 200^il of distilled water. Concentration of both 
hydrolyzed and non-hydrolyzed extract was 0.2mgAnl. Values are 
mean 土 S.E.M. with n=6. "a" means p > 0.05 compared to the 
untreated control by student's t-test. 
t 
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Figure 2.7 Paper chromatography of acid hydrolyzed extract. The volume added in 
each lane was lO^il. The running method is same as 2.3.3.4. Lane 1 is 
O.lM NaOH polyamide resin eluate. Lane 2 is acid hydrolyzed O.lM 
‘ NaOH eluate. Lane 3 is fraction 6 of Spehadex LH-20. Lane 4 is acid 
hydrolyzed Sephadex LH-20 eluate. Lane 5 is fraction 3 of RP-HPLC 
and lane 6 is acid hydrolyzed RP-HPLC eluate. 
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2.3.4.4 Identification of monosaccharide in purified extract of Prunella 
vulgaris by thin layer chromatography (TLC) 
Apart from paper chromatography, the acid hydrolyzed extracts were 
also subjected to TLC analysis in order to identify various isomers of 
monosaccharides in the extracts. Eighteen monosaccharides or disaccharides were 
included as standard in the analysis. The colour development reagent was to 
reduce carbohydrate by ionic silver in the reagent and a brown spot was produced 
(Jork et aL, 1990). The result was shown in Figure 2.8. A brown spot was found in 
all the sample having a Rf value of 0.876 except the crude extract in which a 
brownish smear was found instead. When compared the non-hydrolyzed with the 
hydrolyzed extracts, it was found that the colour intensity of non-hydrolyzed one 
is less intense than that of hydrolyzed one. Moreover, the colour intensity of 
different eluate were different. The colour intensity of non-hydrolyzed extract 
increased from O.lM NaOH polyamide resin eluate to RP-HPLC eluate. This can 
be found in hydrolyzed extract as well. The hydrolyzed extract of RP-HPLC 
showed the most intense colour suggesting that the monosaccharide released. 
(Table 2.13) 
71 
Table 2.13 Rf vahie of non-hydrolyzed and hydrolyzed eluate and standard 
carbohydrates. 
Sugar Sample R^ 
Crude extract . 
O.lM NaOH polyamide resin eluate 0.876 
Acid hydrolysis of O.lM NaOH polyamide resin 0.876 
eluate 
Sephadex LH-20 eluate 0.876 
Acid hydrolysis of Sephadex LH-20 eluate 0.876 
RP-HPLC eluate 0.876 















D-galacturonic acid 0.727 
Polygalagcturonic acid N.D. 
Mannosamine 0.756 
a-D+ melbiose 0.881 
Rf was calculated by distance of sample migrated from origin / 
solvent front. Solvent front is 13.7 cm. Rf of crude extract 
cannot be calculated and no distinct spot was identified. N.D.: 
Not determined. 
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Figure 2.8(A) Thin layer chromatography of non-hydrolyzed eluate and hydrolyzed 
eluate from various fractionated extracts of Prunella vulgaris. An 
amount of lO^il of sample and 2^1 of standard was loaded to TLC 
plate (20cm X 20cm). The condition of and colour development of 
TLC was descibed in 2.2.6.2. Lane 1 is crude extract. Lane 2 is O.lM 
NaOH eluate from polyamide resin eluate. Lane 3 is acid hydrolyzed 
0.1M NaOH eluate. Lane 4 is fraction 6 of Sephadex LH-20. Lane 5 
“ is acid hydrolyzed Sephadex LH-20 eluate. Lane 6 is fraction 3 of 
. RP-HPLC. Lane 7 is acid hydrolyzed RP-HPLC eluate. Lane 8 is D-
arabinose. Lane 9 is a-D-+-fiicose. LanelO is D+galactose. Lane 11 
is D+galactosamine and lane 12 is N-acetyl-D-galactosamine. 
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Figure 2.8(B) Thin layer chromatography of standard carbohydrate (continue). 
Lane 1 is glucose. Lane 2 is D + glucosamine. Lane3 is D + mannose. 
Lane 4 is raflHnose. Lane 5 is L+ rhamnose. Lane 6 is D- ribose. Lane 
7 is sucrose. Lane 8 is a-D- talose. Lane 9 is xylose. Lane 10 is D-
galactumoic acid. Lane 11 is polygalactouronic acid. Lane 12 is 




2.3.5 Specificity ofthe purified extract on polymerase inhibition 
2.3.5.1 Inhibition ofpurifiedPrM«e//fl vulgaris extract on Taq polymerase 
In order to test whether the purified extract can also show inhibition to 
polymerase other than fflV RT, an experiment was done to test the effects ofthese 
extracts on Taq polymerase activity. Inhibition was demonstrated by the inhibition 
of the PCR reaction. As the eluate ofeach steps ofpurification as well as the crude 
extract was added in a PCR reaction using primer set for endothelin-1 PCR. Five 
samples were used including the crude extract, O.lM NaOH eluate from 
polyamide resin, methanol eluate from polyamide resin, Sephadex LH-20 eluate 
and RP-HPLC eluate. It was found that the extracts exhibit inhibition on Taq 
polymerase as indicated by the failure ofamplification ofPCR fragment (-600bp) 
in a PCR reaction (Figure 2.9). 
2.3.5.2 Effect of purified Prunella vulgaris extract on Superscript II 
Apart from using Taq polymerase to examine the specificity of the purified 
extract, superscript II was used. Superscript II is a reverse transcriptase that used 
for.RT PCR which has similar function as HIV RT. Therefore, it was chosen as 
another enzyme for the experiment. The in vitro assay for superscript II can be 
adapted with the HTV RT assay as described in the materials and methods. In this 
experiment, five samples were used including crude extract, O.lM NaOH eluate 
from polyamide resin, methanol eluate from polyamide, Sephadex LH-20 eluate 
and RP-HPLC eluate. From the result obtained, all extracts showed high 
percentage ofinhibition on superscript II. Lnhibition of crude extract, O.lM NaOH 
eluate from polyamide resin, methanol eluate from polyamide, Sephadex LH-20 
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eluate and RP-HPLC eluate were 91.45%, 90.31%, 90.1%, 90.67% and 89.69% 
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Figure 2.9 Effect of purified Prunella vulgaris extract from various steps of 
purification on PCR inhibition. Human endothelin-1 PCR was used in a 
PCR reaction using human endothelial cell cDNA as template. This 
PCR reaction results in a specific amplification of -600bp fragment. 
The concentration of extract used is 0.2mg/ml which is same as the one 
used in HTV RT. The method ofPCR has been described in 2.2.6.4. the 
- gel used us 2% agarose gel in IX TAE. The electrophoresis was run for 
45 min at constant voltage 100V and the PCR band were visualized by 
r 
UV transluminator. Lane 1 is negative control. Lane 2 is positive 
control. M is 100bp DNA marker. Lane 3 is fraction 3 of RP-HPLC. 
Lane 4 is fraction 6 of Sephadex LH-20. Lane 5 is methanol eluate. 
Lane 6 is O.lM NaOH eluate and lane 7 is crude extract. 
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Table 2.14 M:iibition of purified extract from various steps of purification on 
Superscript II inhibition. 
Sample % Inhibition 
Crude Extract 91.45t0.33 
Polyamide resin eluate by 0.1M NaOH 90.31 士 0.15 
Polyamide resin by methanol 90.1 土 0.25 
Sephadex LH-20 eluate 90.67 土 0.59 
RP-HPLC eluate 89.69 土 0.25 
The volume of enzyme used was 20^il of lU/^1 
Superscript II and the assay method is same as HTV RT in 
vitro assay but the superscript II was used instead. The 
concentration of purified extract used was 0.2mg/ml 
which was same as the one used in HrV RT assay. Values 




HrV reverse transcriptase is an important enzyme in the life cycle of HIV. It 
is used to reverse transcribe the viral RNA to DNA which can integrate into host 
DNA. Nucleoside analogue has been found to have inhibitory activities to HP/ RT. 
However, these compounds have many side effects and drug resistance was 
observed due to high mutation rate of the virus. Therefore, the search for new 
drugs is an ongoing objective for AIDS therapy. Ln this regard, traditional Chinese 
medicine provides an alternative source of new drugs for AJDS therapy. 
Thirteen herbs which were previously shown to inhibit HP/ infection were 
tested (Chang et al. 1988). Both the methanol and hot water extraction procedures 
were carried out. Two extracts were found to have inhibition activities to HTV RT 
> 90%. They are the methanol extract of Coptis chinensis and water extract of 
Prunella vulgaris. These result suggest that some compounds in these two herbs 
specifically inhibit HFV RT. The water extract of Prunella vulgaris was chosen for 
further purification and characterization. The herbs were found to have several 
kinds of metal compounds such as magnesium, potassium, sodium, zinc, calcium 
and manganese (Duke, 1992). Dialysis was performed to remove these compounds 
before HIV RT assay. Therefore, the inhibitory activity of Prunella vulgaris 
extract is not due to high amount of metal that may interfere the assay. 
Several experiments were done to characterize the active compounds. 
Protease digestion of the extract did not affect the inhibitory activities. This result 
indicates that the active components are not protein or peptide. Previous study 
reported that extracts of Prunella vulgaris was able to inhibit HIV infection. The 
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active components may be due to polysaccharide (Tabba et al., 1989). To confirm 
whether the same activity is responsible for HrV RT inhibition, the extract was 
digested with a - and p-glucosidase in order to remove the glucose moiety. It was 
found that neither a-glucosidase digestion nor p-glucosidase digestion 
significantly affect the inhibitory activities. It suggests that the active components 
may not be a glucoside or the glucose moiety is not essential for activity. Another 
method to remove polysaccharides were the oxidation by NaIO4 as described by 
De Ruiter et al (1994). Polysaccharides were treated with NaIO4 and then 
dialyzed to remove the oxidized carbohydrates (De Ruiter et al., 1994). Again, this 
treatment failed to alter the inhibitory activity. Taken together, it seems unlikely 
that the active component is a polysaccharide. 
Prunella vulgaris is known to contain several kinds of triterpenoids. 
Triterpenoids are compounds with a carbon skeleton based on six isoprene units 
which are derived biosynthetically from the acyclic C30, squalene. They have 
relatively complex cyclic structures, most being either alcohols, aldehydes or 
carboxylic acids. Triterpenoids can be divided into at least four groups of 
compounds: true triterpenes, steroids, saponins and cardiac glycosides (Harbome, 
1973). The most abundant triterpenoids found in Prunella vulgaris are oleanolic 
acid and ursolic acid (Wang et aL, 1993). Therefore, oleanolic acid, ursolic acid 
and oleandrin were tested. However, precipitate was found once the compounds 
were added. Another group of natural products that showed inhibition to HFV RT 
are flavanoids. For example, baicalein (5,6,7-trihydroxyflavne) was previously 
shown to have > 90% inhibition to fflV RT at 2^igAnl (Ono et al., 1989). In my 
study, high concentration of baicalein (1.4mM) exhibited only 41% inhibition to 
HIV RT. Moreover, flavanoids are not the major component in Prunella vulgaris 
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(Duke, 1992). All these suggested that baicalein is not the active ingredient in the 
Prunella vulgaris extract responsible for HIV RT inhibition. 
Several lines of evidence indicate that the polyphenolic compounds in 
Prunella vulgaris may be responsible for the inhibitory activity to HFV RT. 
Several methods were used in order to remove polyphenolic compounds from the 
crude extract. The first method used is PVP precipitation. The mechanism in 
removing tannins is the formation of hydrogen bonds between the tannin phenolic 
hydroxyl groups and the amide link (CONH) of the precipitating agents. The 
presence of PVP did not interfere with the inhibitory effect of test compounds 
(Tan et al., 1991). The result showed that the percentage inhibition of PVP 
precipitated extract was only 11.31% in which the activity was drastically reduced 
compared to the untreated one. It suggests that PVP precipitation treatment can 
remove HFV RT inhibitory activity. Another method to remove polyphenolic 
compounds by adsorption chromatography using polyamide resin. The advantage 
of using polyamide is that non-tannin and tannins substance can be separated in a 
short time (Wall et al, 1969) and it was reported to remove polyphenolic 
selectively. Non-tannin inhibitory compounds with two or three phenolic hydroxyl 
group can be eluted by flushing with methanol (Tan et al., 1989). bi my study, two 
active fractions of eluate were obtained. One eluted by 0%, 50% and 100% 
methanol and the other one by O.lM NaOH. Both fractions were used for HIV RT 
assay. From the result, it was found that the O.lM NaOH eluate have higher 
inhibitory activities than the methanol eluate. The O.lM NaOH eluate with 
acidification was found to give positive result in tannin test (Wall et al., 1969). 
Two naturally occurred tannins were tested. One is tannic acid and the other one is 
catechin. The difference between tannic acid and catechin is that tannic acid 
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belongs to hydrolyzable tannins. Hydrolyzable tannins have structure in which 
polyalcohol (mainly glucose) is esterified with polyphenolic carboxylic acid. 
Catechin belongs to flavan which has the composition of condensed tannins 
O^akashima et al., 1992). Both of these compounds showed some degree of 
inhibition. However, our result showed that the inhibitory activities of Prunella 
vulgaris aqueous extract is much higher than pure tannin which only gave 
marginal inhibition to HrV RT. These data suggests that the active constituents in 
Prunella vulgaris are not due to pure tannic acid or catechin. 
Based on the finding of the composition in Prunella vulgaris water extract, 
further purification was done in order to obtain more pure active constituents for 
characterization. Three steps of purification were involved. The first step is 
polyamide resin absorption chromatography. This step of elution was same as the 
one used in identification of the compounds except the concentration of crude 
extract used. This method can be used to obtain the phenolic compounds in a short 
time. The inhibitory activity may not be due to NaCl produced during acidification 
as the eluate was dialyzed extensively. The inhibitory activity to HIV RT was 
recovered further confirm that the component in O.lM NaOH eluate contains the 
active constituent that can inhibit HIV RT. The next step of purification is by 
Sephadex LH-20 chromatography. The principle of separation by using Sephadex 
LH-20 is gel filtration. This matrix is commonly used for the separation of organic 
compounds based on size exclusion. It can also be used for separation of 
polyphenolic compounds (Cai et al., 1991; Lu et al., 1997). The separation was 
done by increasing concentration of methanol from 0% to 100%. Two peaks were 
obtained (Figure 2.1). Peak 1 was eluted at 37% methanol and peak 2 at 80% 
methanol. Peak 1 gave the higher inhibitory activity to HP/ RT than peak 2. 
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Moreover, peak 1 did not show tailing. Therefore, peak 1 was chosen for further 
separation. Based on the retention time，it is suggested that the molecular weight 
of active components found in peak 1 is higher than the one in peak 2 since the 
separation is based on size exclusion. The final step of purification is using RP-
HPLC separation. Gradient of methanol with 0.1% acetic acid were used. A sharp 
peak and a broad peak were obtained (Figure 2.3). Both the sharp one and a 
fraction ofbroad peak showed inhibition to HIV RT. The inhibition on fflV RT of 
the broad dne is higher than the sharp one. The sharp peak was chosen because it 
appears to be more homogeneous. 
Paper chromatography was performed for all the eluate collected in three 
steps ofpurification in order to detect the presence of phenolic compounds. Folin-
Ciocalteu was used for detection of phenolics. The crude extract gave the longest 
smear indicating the heterogeneity of phenolic compounds. A blue spot with a Rf 
of 0.48 was found in crude extract. However this blue spot disappeared in the 
others suggested that the compounds in this spot are not the active constituents. 
Another blue spot was found in O.lM NaOH eluate and Sephadex LH-20 eluate 
with a Rf of 0.266. However, this spot disappeared in RP-HPLC eluate. Therefore, 
the active compounds may exist in the blue smear and further purification is 
required to get the more pure compounds. 
The purified extracts were used for further characterization. Dose response 
curves of the purified extract were done in order to find out the effective 
concentration. The effective range the extract is between 0.003 to 0.3mg/ml. The 
percentage inhibition of the extract with concentration lower than 0.003mgAnl 
maintain at 40-50%. This may be due to the presence of interfering substrate in the 
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extract. The acid hydrolysis of the extract is to remove the phenolic glycoside (Lu 
et al., 1997). Hydrolysis of eluate from various steps of purification indicated 
that it did not affect the inhibitory activity to HFV RT. This suggests that the active 
constituents may not be glycoside. Both paper chromatography and TLC were 
performed to test the hydrolyzed and non-hydrolyzed extract. A longer blue smear 
was found in hydrolyzed sample indicated that something has been released. 
However, it did not destroy the inhibitory activities to HW RT. Thin layer 
chromatography was performed in order to identify the monosaccharide of acid 
hydrolyzed extract. A brown spot was detected in each sample (Figure 2.8). The 
brown spot is the result of oxidation of monosaccharide by silver ion (Jork et al., 
1990). It suggested that the purified extract contains polysaccharide which can be 
hydrolyzed by acid. Previous study showed that the monosaccharide constituent 
are glucose, galactose, xylose, gluconic acid, galactonic acid and galactosamine 
(Tabba et al., 1989). The Rf of monosaccharide in extract and standard 
monosaccharide were measured. The Rf of the extract was similar to most of the 
standard except D+galactosamine, D+glucosamine, raffmose, D-galacturonic acid 
and mannosamine (Table 2.13). This indicated that they are not the constituent of 
monosaccharide in Prunella vulgaris extract. 
( 
The final test of Prunella vulgaris extract was its specificity to other 
polymerase. Previous studies show evidence that plant polyphenols were 
selectively bound to proteins. The reaction is mainly through hydrogen bond and 
hydrophobic interactions. In general, the extent ofbindings is related to molecular 
weight of polyphenols and is determined by protein size and condition of reaction 
(Zhu, et aL, 1996). The specificity ofthese extracts to HW RT were examined by 
testing the inhibitory activities to the other polymerase. Two polymerases were 
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tested and one was Taq polymerase examined by PCR. The other one was 
superscript H which is a reverse transcriptase. The result showed that the active 
fractions similarly inhibited the Taq DNA polymerase and Superscript II. Based 
on these results, the extract exhibited low selectivity to HTV RT. Therefore, it can 
be proposed that the inhibition mechanism may be due to an inhibition of 
polymerization process regardless of the types of polymerase involved. 
The aqueous extract of Prunella vulgaris was previously reported to have 
anti-HIV activity. Prunellin was isolated from this extract. This is a sulfated 
polysaccharide which inhibits HrV-replication in different cell line such as 
lymphoid cell line MT-4, monocytoid cell line U937 and peripheral blood 
monoclear cells. The mechanism for its action is to prevent viral attachment to the 
CD4 receptor (Yao et al., 1992). Moreover, the aqueous extract of this herb was 
also reported to inhibit HIV RT significantly (Collins et aL, 1997). This study 
further confirm that Prunella vulgaris contains anti-HIV constituents. Compounds 
different from sulfated polysaccharide were found from the aqueous extract of 
Prunella vulgaris. Apart from preventing viral attachment to the CD4 receptor, 
this study clearly demonstrated that the same extract is able to inhibit HTV RT. 
Described in the following chapter, preliminary result shows that the same 
extracts also had inhibitory activities to HIV protease. All these data suggests that 
elucidation of the structure of active constituents in Prunella vulgaris extract may 
help us to search for new drug for anti-AIDS therapy. 
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Chapter 3 Screening of traditional Chinese medicinal (TCM) plants for HIV 
protease inhibition 
3.1 Introduction 
3.1.1 HIV Protease structure and function 
� HIVProtease Structure 
HIV protease belongs to the family of aspartic protease since a pair of highly 
conserved aspartyl residues constitute the catalytic groups at their active sites 
(Meek, 1989). HTV protease is a C2-symmetric homodimer composed of two 
identical 99 amino acid monomers. The active site contains a conserved sequence 
Asp-Thr-Gly at residue 25-27 of each monomer QSfavia et al, 1989). The active 
site is stabilized by hydrogen bonds involving the threonine residue at position 26, 
which forms rigid network referred to as a 'fireman's grip’ (Wlodawer et al., 
1989). The enzyme contains two conserved domains: domain I is Leu-LeufVal)-
Asp-Thr(Ser)-Gly-Ala and domain H is Ile(Leu)-Leu-Gly-Arg-Asp (Toh et al., 
1985). Apart from this, the fflV-l protease contains two folded f> hairpins that 
form a flap which covers the enzyme active site (Appelt, 1993; Wlodawer et al., 
1993). 
(B) Function of HWProtease 
During the life cycle of tHV, specific viral proteins are produced. The 
polyprotein was translated from the gag and pol gene. The products are Pr55^^^ 
and Prl60^ag-Po/ Pr55^^^ is produced by direct translation from gag gene. It is a 
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55kDa polyprotein which contains structural protein o f H W such as pl7, p24, p7 
and p6 (Ratner et al., 1985; Sanchez-Pescador et al., 1985) Prl60^ag-po/ -^  
produced by frameshift translation. It is a 160kDa protein which contains both 
structural protein and viral enzyme such as HFV reverse transcriptase, HIV 
integrase and HTV protease (Veronese et al., 1986). HFV protease specifically 
cleaves the viral polyprotein into the functional enzymes and structural proteins of 
the virion core. This processing is the final stage for the replication cycles of HIV. 
Only eight cleavages were required for the complete proteolytic processing (Darke 
et al., 1988). Three cleavage sites are of the sequence Ser(Thr)-Xaa-Yaa-Phe(Tyr) 
*Pro. This is the unusual cleavage site for other endopeptidases and is only 
specific for retroviral protease (Pearl et al., 1987). The actual mechanism by 
which proteolytic processing is initiated is unknown. 
3.1.2 Natural products against HIV protease 
Although synthetic HrV protease inhibitors have been developed and 
approved by FDA for clinical use, there is also of interest to find active natural 
products that can inhibit HTV PR. To date, two groups of compounds were shown 
to "have inhibition to HW PR. One group of naturally occurring compounds are 
fIavones. The hydroxyl substituents and a phenolic group at suitable position 
could act as hydrogen-bonding donors or acceptors to engage amino acid side 
chains present in the substrate-binding cleft of the enzyme. This interaction might 
prevent access to the active site region by incoming polypeptide substrate. 
Flavones were considered as potential inhibitors as they can easily fit into the 
active site. One possible mechanism of action is that the 2-phenyl substituent 
occupy the Pi pocket which has been demonstrated by crystallographic studies in 
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both free enzyme and inhibitor-bound form (Brinkworth et al., 1992). 
Another group of naturally occurring compounds are terpenoids. Two 
diterpenes, camosolic acid and camosol were used to test the HTV PR inhibitory 
activities. It was found that camosolic acid have the strongest inhibitory effect at 
cell free assay. The IC90 is 0.08jigAnl. The compound was used to assay the 
inhibitory effect of HW-l virus replication. It was found that the TC90 on H9 
lymphocyte was 0.36p,gy'ml. In addition, this compound did not inhibit cellular 
aspartic protease cathepsin D and pepsin at the concentration range up to 10|igAnl 
(Paris et al,, 1993). Several non-peptide inhibitors ofHrV-1 protease were found 
to inhibit the dimerization of the protease. Triterpenes fit well into the 
hydrophobic interface site of relaxed monomer by computer docking. It was found 
that ursolic acid belongs to the group of dimerization inhibitor with Kj*^ '^  3.4^iM 
(Quere et aL, 1996). Ursolic acid is easily found on the waxy skin of apple. One 
single apple with waxy skin contains more than 50mg of ursolic acid (Ying et cd., 
1991). Therefore, cheap but potent HrV protease inhibitory agent can be 
developed. 
There are also some newly discovered natural products that show potent 
inhibitory activity against HP/ PR. Mangostin and y-mangostin which were 
isolated from ethanol extract of Garcinia mangostana L. (Guttiferae) are potent 
inhibitors with an IC50 of 5.12 土 0.41^tM and 4.81 土 0.32|iM respectively. The 
kinetics of these two compounds have been studied and both of them shown non-
competitive inhibition with Ki 10.7 士 0.95^iM and 7.8 土 0.4nM for mangostin and 
y-mangostin respectively (Chen et al., 1996). 
88 
3.1.3 Plant extracts against HIV protease 
Plant crude extracts were screened and some of them show strong inhibition 
on HIV PR. hi a series of study on seventy-five traditional medicines from China, 
Japan and Monesia, it was found that 18 plants showed more than 70% inhibition 
at the concentration 250^g/ml. Moreover, five were found to be effective at the 
concentration 25\ig/m\ including Belamcanda chinensis ， Magnolic fargesii, 
Paeonia suffiuitcosa, Phellodendron amurense and Terminalic chebula. Six of 18 
plant extracts that exhibited more than 70% inhibition on HTV protease contain 
many phenolic compounds and tannins such as the aqueous extracts of Geum 
japonicum, Punica granatum, Phus Javanica, Terminalia arjuna, Terminalia 
chebula and Woodwardia orientalis (Grampuroghit, 1986; Fukuchi et cd., 1989; 
Lin et al., 1990; Xu et aL, 1993;1994). Extract from Anemarrhena asphodeloides, 
Epimedium sagittatum, Oldenlandia diffusa, Phellodendron amurense, Sophora 
japonica and Taraxacum mongolicum also showed strong inhibitory activity 
against HW PR. pCu et al, 1996). 
][n another study, two hundred and thirty one ethanoL^aqueous extracts from 
the New Zealand plants were screened. It was found that sixteen of 231 crude 
extracts showed more than 30% inhibition at the concentration 50^g/ml. 
Confirmation of the activities were examined by HPLC assay. It was found that 
Elaeoaarpus hookerianus, Cassinia leptophylla, Pernettya macrostigma and 
Pseudotsuga menziesii exhibited high inhibitory against HW PR (Wan et aL, 
1996). Pseudotsuga menziesii was further purified and dihydroquercetin and 
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[5‘5']-disdihydroquercetin were isolated (Foo et al., 1992). The symmetric 
structure of [5 ‘ 5 ']-bisdihydroquercetin is thought to fit the structural requirement 
ofcompetition for the enzyme active centre with its substrate (Wan et al., 1996). 
Screening of plant extracts traditionally used in Lndia showed that some of 
them inhibited HTV PR at the concentration 0.2mg/ml including aqueous extracts 
of Areca catechu, Saraca indica Terminalia arhjuca, Eugenia jambolana, Ficus 
reliogiosa, Litsea sebifera, Myristica fragrans, Pogfostemon heynaenus, Rhus 
acuminata and Terminalia chebula as well as methanol extracts ofAreca catechu, 
Eugenia jambolana, Terminal arjuna, Cassia fistula，. Mimusops dlengi and 
Terminalia chebula. Areca catechu showed the most potent inhibitory effect with 
an IC50 of 12ng/ml. The activity is even stronger than the known inhibitor, 
acetylpepstatin. After isolation and identification, a procyanidin dimer 
(procyanidin B1) and two trimers (arecatannins Al and B1) were isolated. It was 
found that the inhibitory effects increased in the order of procyanidin B1, 
arecatarmin Al and arecatannin B1 depends on the extent of condensation of the 
monomeric units (Kusumoto et aL, 1995). 
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3.2 Materials and methods 
3.2.1 Materials 
Ampicillin, chloramphenical, imidazole, polyethylene glycol MW8000, 
bovine serum albumin, HIV protease substrate (Acetyl-Ser-Gln-Asn-Tyr-Pro-Val-
Val-Amide), N-terminal cleavage fragment of HFV protease substrate Acetyl-Ser-
Gln-Asn-Tyr, dithiothretiol, glycerol and ethyl glycol were obtained from Sigma. 
DEAE Sepharose CL-6B was obtained from Pharmacia. Trifluoroacetic acid, 
acetonitrile (HiPerSolv) were obtained from BDH. Dialyzing membrane with 
3500 MWCO was obtained from Spectrum. Bradford Reagent, mini-Protean H 
electrophoretic system, acrylamide, bis-acrylamide, ammonium persulfate, 
N' ,N' ,N' ,N',-teraiethylethylenediamine (TEMED), SDS-PAGE Prestained marker 
(MW range 7.4kDa to 203kDa) and Econo-column were obtained from Bio-Rad. 
m V protease substrate 1 (H-2930) with sequence Arg-Glu(EDANS)-Ser-Gln-
Asn-Tyr-Pro-Ile-Val-Gln-Lys(DABCYL)-Arg was obtained from Molecular Probe. 
Ninety six well sterilized plate was obtained from Coming. 
Cytofluor 2350 was obtained from Millipore. HPLC system including 600S 
controller, 486 tunable absorbance detector and 717 autosampler was obtained 
from Waters. Vydac Cig Protein^eptide Reverse Phase Column 218TP was 
obtained from Separation Group. 
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3.2.2 Expression ofHIV protease 
3.2.2.1 Expression and purification of HIV protease 
AJ Selection of the Appropriate Clone 
Recombinant HIV protease cDNA was a generous gift from Dr. Jordan J. N. 
Tang in Oklahoma Medical Research Foundation. HTV protease cDNA was 
cloned into expression plasmid vector pET3b as described by Lin et al. (1994). 
The plasmid was transformed into E. coli BL21(DE3)pLysS. The transformed 
bacterial stocks were stored in 10% glycerol at -70°0. Screening of bacterial 
colonies was done by streaking the frozen bacteria glycerol stock on LB agar plate 
containing 34^ig/ml chloramphenical and 50^g/ml ampicillin. After an ovemight 
incubation, 9 colonies were picked and grown in 2ml LB broth with 34^igAnl 
chloramphenical and 50^ig/ml ampicillin at 37�C for 6 hours with orbital shaking 
at 200 rpm. After growing for 6 hours, 0.5ml was taken for SDS-PAGE and 0.5 
ml for preparing glycerol stock. 0.4mM of ffTG was added into the remaining 
1ml bacterial culture and then grow for 2 hours for the induction of recombinant »• 
HIV protease. 
B) Large Scale Expression of Recombinant HU^ Protease 
The clone that was demonstrated to express HTV protease as indicated by 
SDS-PAGE was used for a large scale culture. The remaining 0.5 ml bacterial 
culture was added into 200ml LB-broth containing both chloramphenical and 
ampicillin with concentration mentioned above. After growing at 37°C with 
shaking at 200rpm until the optical density at 600nm reach 0.3-0.5，1 ml culture 
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was stored and EPTG was added into the remaining culture to a final concentration 
0.4mM. After incubation at 37°C for 2 hours with shaking, the bacteria was 
collected by centrifugation at 5000 rpm for 15 minutes. The supernatant was 
discarded and the pellet was resuspended in 20ml of IX binding buffer (5mM 
imidazole, 0.5M NaCl, 20mM Tris-HCl, pH 7.9). After sonication for 3 minutes 
and centrifugation at 13000 rpm for 15 minutes, the supematant was removed and 
the pellet was resuspended in 20 ml IX binding buffer. The washing procedure 
was repeated two times and the pellet was finally dissolved in 10 ml buffer B 
(lOmM Tris-HCl, pH 7.4, 8M urea and lOmM DTT). After removing undissolved 
protein by centrifugation at 18000 rpm for 15 minutes at 4°C, the protease solution 
was then passed through a DEAE Sepharose CL-6B column (2.2 X 9 cm Bio-Rad 
Econo-column) pre-equilibrated with buffer B at 4°C. The column was eluted with 
buffer B and 1 ml per fraction was collected, monitored at uv 280nm. The 
breakthrough peak was collected. The whole chromatographic procedure was 
performed at 4�C. 
C) Purification of Recombinant HB^ Protease 
‘The protease solution was dialyzed against 2L solution containing lmM DTT, 
1% (v/v) glycerol and lOmM sodium acetate, pH 3.5 at 4 � C overnight. The 
solution was then centrifuged at 10000g for 20 minutes. The supematant was 
dialyzed using dialyzing membrane with 3500 MWCO. The dialysate was then 
concentrated by polyethylene glycol MW8000 to 5ml. The purified HIV protease 
was stored at -70°C until assay. 
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C) Protein Concentration Determination 
The protein concentration was determined by the Bradford method (1976) 
and bovine serum albumin was used as protein standard. 
3.2.2.2 Sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-
PAGE) 
SDS-PAGE was performed according to the method ofLaemmli (1970). The 
gels were casted according to the instruction manual in the Bio-Rad mini-Protean 
II system. 
A) Preparation of SDS-Polyacrylamide Gel 
The gel consisted of 15% separating gel (1.0 mm thick and 5 cm long). It 
composed of 30% acrylamide mix (29% acrylamide and 1% bis-acrylamide), 
1.5M Tris pH 8.8，10% SDS. 5% stacking gel was set with 30% acrylamide mix, 
l.OM Tris-HCl pH 6.8, 10% SDS. The gel was polymerized by adding 10% •» 
ammonium persulfate and TEMED. 
B) Preparation of Protein Sample 
Both uninduced and induced protein fraction were collected and centrifuged 
at 13000rpm for 5 minutes. The resulting pellet was resuspended in 50^1 of IX 
loading buffer (50mM Tris-HCl pH 6.8，100mM DTT，2% SDS, 0,1% 
bromophenol blue and 10% glycerol) and boiled for 20 minutes. After 
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centrifiigation at 13000 rpm for 5 minutes, 10|il of protein samples were loaded 
into each well. Five |il of prestained SDS-PAGE prestained marker was loaded as 
molecular size marker. 
C) Electrophoresis Condition 
Electrophoresis was run in a buffer containing 25mM Tris, 250mM glycine 
pH 8.3 and 0.1% SDS at constant voltage of 120V. Electrophoresis was stopped 
until the dye front is at the bottom of the gel. 
3.2.3 Characterization of HIV protease 
3.2.3.1 HIV protease assay by fluorometric method 
The m V protease fluorogenic substrate (Arg-Glu(EDANS)-Ser-Gln-Asn-
Tyr-Pro-Ile-Val-Gln-Lys(DABCYL)-Arg) was dissolved in dimethyl sulfoxide 
(DMSO) to make a lmM stock. The substrate was covered with tin foil and kept 
in -20�C. 
»«• 
“The assay was performed in 96-well sterilized plates. The stock fluorogenic 
substrate was diluted to lOOp,M by the assay buffer which contained O.lM sodium 
acetate, lM NaCl, lmM EDTA, lmM DTT, 10% DMSO and lmg/ml BSA, pH 
4.7. DTT and BSA were freshly added into assay before use. The total reaction 
volume was 200^il. An amount of lO i^l of substrate (lOO^iM) and 5 ^1 of HIV 
protease solution (1.3 ^ig/^l) were added carefully to avoid bubble formation. The 
plate was covered by wet paper towel and placed in zip-lock bag and incubated at 
37°C for 1 hour. The fluorescence intensity was measured by CytofIuor 2350 with 
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an excitation wavelength of 340 nm and an emission wavelength of 490 nm. The 
sensitivity was adjusted to 6. 
3.2.3.2 HIV protease assay by using reverse phase high performance liquid 
chromatography (RP-HPLC) 
A) Preparation of HFVProtease Substrate and Product 
Both the HTV protease peptide substrate and N-terminal digested product of 
the substrate were dissolved in 1 ml of nanopure autoclaved water to give final 
concentration to lmM. Both the peptide substrate and product were kept at -20°C. 
B) HIVProtease Digestion 
The stock peptide substrate was diluted to lOO i^M in nanopure autoclaved 
water and was kept on ice. The assay was done in 1.5ml microcentrifuge tube in a 
total reaction volume of lOO i^l composed of 50mM sodium acetate, pH 5.5. O.lM 
NaCl, 10% glycerol, 2.5% ethylene glycol and O.lM DTT. DTT was freshly added 
before starting reaction. Five i^l of HIV protease peptide substrate (lOOp,M) with 
r 
final concentration 5 i^l and 15p,l of HFV protease solution (1.3^g/p,l) was added 
and incubated at 37°C for 2 hours. The reaction was stopped by adding lOp,l of 
5.5% trifluoroacetic acid (TFA) to a final concentration of 0.5%. After mixing by 
vortex, the tubes were centrifuged at 13000 rpm for 5 minutes. The resulting 
supematant was kept at 4°C until assay by RP-HPLC. 
Q Preparation of HPLC Solvent and Equilibration of Column 
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Solvent A contains 0.1% trifluoroacetic (TFA) in nanopure water and the 
solvent B contains 80% acetonitrile in 0.1% TFA. The solvent A and solvent B 
were degassed by ultrasonication for 30 minutes. The C18 protein/peptide reverse 
phase column CVydac C18 218TP) was equilibrated in solvent B overnight at a 
flow rate of 0.1 mVmin and then equilibrated in solvent A for 1 hour at the same 
flow rate. The chromatography was carried out on Waters HPLC system equipped 
with 600S controller, 486 tunable absorbance detector and 717 autosampler. 
D) Reverse Phase High Performance Liquid Chromatography (RP-HPLC) 
An amount of 50^il of assay volume was loaded using an autosampler kept at 
4°C. The eluate was monitored at uv 214nm at a flow rate of 0.6mVmin. the 
column was eluted with a gradient according to the following table 
Time (min.) FlowRate(mlAnm) Solvent A (%) Solvent B (%) 
1 ^ ioo 0 
^ 31 0.6 70 30 
36 0.6 0 100 
‘ 4 1 0.6 0 100 
42 0.6 100 0 
60 0.6 100 0 
Under this condition, the substrate was eluted at the retention time of 30 min and 
the digested peptide was eluted at 20 min. 
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3.3 Results 
3.3.1 Expression ofHIV protease 
HIV protease gene was cloned in an expression vector pET3b and was 
transformed into E.coli BL21(DE3)pLysS. After two hour ofIPTG induction，the 
recombinant HTV protease was expressed. The expressed protein was 
demonstrated by SDS-PAGE using 15% polyacrylamide gel with a protein band at 
molecular weight llkDa. The protein was found in inclusion body bands and 
inclusion body enriched samples (Figure 3.1). An amount of 65mg of HP/ 
protease could be recovered. 
3.3.2 HFV protease assay 
3.3.2.1 HIV protease assay by using reverse phase HPLC 
Two HFV protease assay systems were used to validate the specificity and 
activity of recombinant HrV protease. The first assay is by the use of a synthetic 
peptide as substrate. After digestion of substrate with the fflV protease, the 
H 
digested products were subjected to reverse phase HPLC to confirm the specific 
r 
cleavage ofthe peptide as shown in Figure 3.2. The retention time of the substrate 
was 30 min while the retention time of the N terminal cleavage product was 20 
min. The cleavage was inhibited in the presence of lO^iM pepstatin A. The 
enzymatic cleavage was enzyme concentration dependent and time dependent 
(Figure 3.3). 
3.3.2.2 HIV protease assay by using fluorometric measurement 
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Another method for the assay ofHIV is by the use of a fluorogenic substrate. 
After the cleavage of the fluorogenic substrate by HT/ protease, the quantum yield 
of fluorescence intensity of the product increase dramatically and the increase in 
fluorescence intensity is directly proportional to the activity of HrV protease. As 
shown in Figure 3.4，the enzyme activities were proportional to the amount of 
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figure 3.1 SDS-PAGE analysis of recombinant HTV protease expression. 15% of 
Polyacrylamide gel was used. Lane 1 is uninduced fraction. Lane 2 is 
induced fraction. Lane M is marker. Lane 3 is supernatant 1 of 
sonication during purification of inclusion body. Lane 4 is supernatant 2 
„ of sonication. Lane 5 is supernatant 3 of sonication. Lane 6 is the 
protein dissolved in buffer. 
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Figure 3.2 Chromatogram of RP-HPLC assay of fflV protease. (a) The 
chromatogram of HrV protease assay. (b) The chromatogram of HIV 
protease with pepstatin A. (c ) The chromatogram of HIV protease 
when the enzyme was boiled. Product peak was indicated by 1 and 
substrate peak was indicated by 2. P means product. S means substrate, 
(d) Product peak, (e) Substrate peak. 
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Figure3.3 The effect of enzyme concentration on the enzyme activities of HIV 
protease. The enzyme activities was calculated by concentration of 
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Figure 3.4 Fluorogenic measurement of recombinant HIV protease activity. The 
concentration of fluorogenic substrate used was 10|iM and the 
incubation time was one hour. The excitation wavelength was 360nm 
“ and emission wavelength was 460nm. The circle is enzyme activities 
• of recombinant HW activities. The square is recombinant HIV protease 
activities with pepstatin A added. 
103 
3.3.3 Screening of crude Chinese medicinal extracts on inhibition of HIV 
protease 
3.3.3.1 Methanol extracts 
The expressed HrV protease was then used for screening of herbal extracts 
for inhibitory activities to the enzyme. The first step was to examine the methanol 
extract of these herbs on HW protease. Fluorometric method was first applied in 
order to find out the leading extracts having inhibitory activities to the enzyme. 
RP-HPLC method was then used in order to confirm the specific cleavage site by 
the enzyme. The concentration of 0.2mg/ml and 0.02mg/ml crude extracts were 
used for the assay. The five methanol extracts having inhibitory activities higher 
than 50% at 0.2mg/ml are C. chinensis, V. yedoensis, C moriforlium, W. 
unigemmata and S, scandens. The remaining methanol extracts shown inhibitory 
activities between 5% to 40% including P. vulgaris, A. lappa L, L japonica, F. 
cirrhosa, C. indicum, L. erythrorhizon, S. flavescens and A. paniculata. The 
methanol extract of Woodwardia unigemmata exhibited the highest inhibitory 
activities in the assay (97.57% at 0.2mg/ml and 40.7% at 0.02mg/ml) (Table 3.1). 
Extracts with percentage inhibition higher than 50% at the concentration 
0.2fng/ml were chosen for RP-HPLC assay. They are Coptis chinensis, Viola 
yedoensis, Chrysanthemum moriforlium, Woodwardia unigemmata and Senecio 
scandens. Both concentrations were used for RP-HPLC assay. From the 
chromatogram obtained, no product peaks were found when 0.2mg/ml of 
methanol extract of these five extracts were added. Product peaks were found 
when the concentration of extracts was 0.02mg/ml (Figure3.5). 
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3.3.3.2 Water extracts 
Apart from the methanol extract, water extracts of the thirteen Chinese herbal 
medicine which were used in screening for inhibition on HTV RT were used. The 
assay method was same as the one used in methanol extract screening. 
Fluorometric measurement was used first in order to find out the extract which 
showed inhibitory on HrV PR. Then RP-HPLC was used to identify the cleavage 
site. From the result of fluorometric measurement, six extracts showed > 50% 
inhibition at the concentration 0.2mgy'ml which include V. yedoensis, C. 
moriforlium, P. vulgaris, W. unigemmata, A. paniculata and S. scandens, three 
extracts showed percentage inhibition between 20% to 50% at the concentration 
0.2mg/ml which include C. chinensis, L erythrorhizon and L. jaopnica. The 
remaining 4 extracts showed percentage inhibition, below 20% including F. 
cirrhosa, C, indicum, A. lappa L and S. flavescens. The extract showed the 
highest inhibition was Prunella vulgaris which has percentage inhibition of 
95.24%. Inhibitory activities of water extract at concentration 0.02mgy'ml were 
also examined. Eleven out of thirteen extracts showed percentage inhibition below 
t* 
15%. Only two extracts showed percentage inhibition at 25.4% and 40.1%. The 
extracts are Prunella vulgaris and Woodwardia unigemmata respectively (Table 
3.2). The extracts which showed percentage inhibition higher than 50% were 
chosen for RP-HPLC assay. Both concentrations were used for the assay. Product 
peaks cannot be found in all the water extracts with concentration 0.2mgy'ml. 
However, Prunella vulgaris showed difference at concentration 0.02mg/ml to the 
others indicating that even at this concentration, the HTV PR activity was totally 
inhibited (Figure 3.6). 
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Table 3.1 Screening of methanol extracts from the Chinese medicinal herbs on 
inhibition o f H W protease activity by the fluorometric method 
% Inhibition % Inhibition 
Name (0.2mg/ml Extract) (0.02mg/ml extract) 
Fritillaria cirrhosa (川貝) 4 . 5 t l . 8 8 9.57 土 7.72 
Chrysanthemum indicum (野菊花） 4.57 土 3.38 3.14 土 1.73 
Coptis chinensis (黃蓮） 87.29 土 2.43 29.75 土 1.78 
Lithospermum erythrorhizon (紅紫草）6.83 土 1.87 2.56 土 1.49 
厂/0/^ ?： 6^^ /06««^ />?(紫花地丁） 62.19± 1.84 19.24土2.16 
Chrysanthemum moriforlium (榜棋菊）58.4 土 3.57 21.12 土 2.39 
Prunella vulgaris (夏枯草） 32.04 士 1.32 25,4 土 1.33 
Arctiun lappa L (牛等子） 23.2 士 3.73 5.96 土 2.94 
Woodwardia unigemmata (貫仲） 97.57 土 1.41 40.7 土 2.49 
Sophoraflavescens (苦參） 10.53 土 2.04 0 
Andrographispaniculata (穿心蓮） 14.44 土 2.77 0 
Lonicera japonica (金銀花） 38.21 土 1.42 23.33 土 3.76 
Senecio scandens (千里光） 91.7 土 2.58 14.96 土 3.09 
^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^l^^llj^„g^^H„BBBaBB„IBPI(((»BIB*l||«ilil«l«^™»l«»l»«*IM"l*««*ll«"«""*«"^^^"^"*"**""*"""""~"^^"^^"^"^"""""""*"*"*"""*«**""«""^^""*"*"""""^*""*^"*"*^*"" 
CoAcentration of the fluorogenic substrate was lO^M and the amount of enzyme 
used was 6.5jig. Intensity of fluorescence was measured at 360nm of excitation 
wavelength and 460nm of emission wavelength after incubation for 1 hour. 
Values are means 土 S.E.M，n=6. 
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Table 3.2 Screening of aqueous extracts from the Chinese medicinal herbs on 
inhibition ofHrV protease activity by the fluorometric method 
% Inhibition % Inhibition 
Name (0.2mgAnl Extract) (0.02mg/ml extract) 
Fritillaria cirrhosa (川貝） 2.07± 1.4 2 . 9 4 t l . 4 
Chrysanthemum indicum (野菊花） 5.43 土 1.62 1.69 土 1.26 
Coptis chinesis (黃蓮） 27.97 土 2.7 2.86 士 1.62 
Lithospermum erythrorhizon (紅紫草）43.93 土 1.47 1.52 土 0.95 
Violayedoensis (紫花地丁） 66.58 土 4.1 9.71 土 2.87 
Chrysanthemum moriforlium (榜棋菊）84.36 士 2.02 13.49 土 4.67 
Prmella vulgaris (夏枯草） 95.24 土 1.2 35.23 土 3.36 
Arctiun lappa [(牛等子） 5.47 土 2.26 2.63 土 1.58 
Woodwardia migemmata (貫仲） 89.7 土 0.81 40.1 土 7.17 
Sophoraflavescens (苦參） 1.93 土 0.9 2.82 土 2.1 
Andrographispaniculata ( 穿 心 蓮 ） 5 0 . 8 5 土 11 2 . 5 3 土 1 . 9 9 
Lonicera japonica (金銀花） 27.95 土 2.44 3.26 土 1.54 
Senecio scandens (千里光） 84.2 土 0.96 14.32 土 3.38 
^^^^^^^^_^^^^^^^^^^^^^^^^^^^^^^^^__^_ l^^ lllll^ ^a^^MMMMMMWMMMMMMmMMHMMMMHMMMnMWMMMMMMMMMHMWMWaMMBHaMMMMMBMMMaMMMMMMMMMMHMMMHMMMMMMMWMMaMMMMMnMHMMMn 
CoAcentration of the fluorogenic substrate was lO^M and the amount of enzyme 
used was 6.5^ig. Litensity of fluorescence was measured at 360nm of excitation 
wavelength and 460nm of emission wavelength after incubation for 1 hour. 
Values are means 土 S.E.M，n=6. 
107 
�-"0 nn r^ ~n 
0.060-丨—cTT rr^ ：| I ‘ 1 :j I . I i i ；！ i 
i . ! 1 1 ！ 0.055-. I ： 
。•叫 ：i丨 i丨丨 s ‘丨丨丨 丨i I •I i ； ！ I ； V i i ；！ j I j ;} ； ！ I ！ I o.oso-! 1 ；1 i ！ I 
� 身 ij I ‘ 丨 I 丨 ！ .丨 丨| I i I 
! I ！ ！ - . . | j ； 
0 . 0 4 S - .； , I ! : •！ : . 
I：丨 I 1 4 ！ , ； j i i ' ！ ；！ ‘ ！ I h ! I 丨1 3-0«-! '\ 丨  1 ra 0.J40- 丨 .1 II 1 丨：丨 P 
i| 丨丨丨4 i :i i |i s 
I ! ‘ . ； •,： . a.o"-i fl :i 1 ‘ ^ 
。•。"： ； i t ~ 1 ! 1 丨 1 
i ； 1访 I 丨|: I 1 
� - I fk � n i ！ , I 
。.。2，： I ^ r : ， • M \丨。|1 / " 
=< 0身 1 j | � V < � -�H i I 1 丨 1 > � 
丨 I j 0.013-i I .�. * 0.0l3- ！ 丨 I j 
i I ,! 
； o.oio- 1\ 
�.�1�- I j I / 
I I ,> f o.ooJ 1丨'\,\1/丨 
。•。。，- i i lill/ ；！ 1 W 
-I I ^ 
一 ； 
O.OQO-U -^  -i \ i :t j 
. ！ • 
1 -0.005-1 ‘ 
- 0 . 0 0 3 - ； -I • -1 .. / i 
- 0 . 0 1 0 - 1 
- O . O l O - i ！ 
! } • 
.i 1 ： 
I -0.0X3-
-0.015-| 
-o.o2?:l"i~"l?:^r~lZ^^~~~^ « •"•"- 乂- ":oo -00 
M^ hOaues: ^ ^ 3 
Hxnuc*a J f ^ ^ ^ ^ ^ »• 
Figure 3.5 RP-HPLC HIV protease assay of methanol extract, (a) RP-HPLC of 
HrV protease assay with 0.2mgy'ml of Woodwardia unigemmata 
methanol extract, (b) RP-HPLC of HrV protease assay with 0.02mgAnl 
of Woodwardia unigemmata methanol extract. 
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Figure i.(5RP-HPLC HIV protease assay of aqueous extract, (a) RP-HPLC of 
HIV protease assay with 0.2mg/ml Prunella vulgaris aqueous extract, 
(b) RP-HPLC mV protease assay with 0.02mg/ml extract Prunella 
vulgaris aqueous extract. 
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3.3.4 Characterization of herbal extracts 
3.3.4.1 Dose response curve of methanol extract of Woodwardia unigemmata 
From the screening of these herbs, it was clearly shown that Woodwardia 
unigemmata methanol extract and the Prunella vulgaris water extract had the 
highest inhibitory activities to HIV PR. Therefore, these two extracts were chosen 
for further characterization. Dose response curve of both the extracts were 
performed. From the dose response curve of Woodwardia unigemmata, it was 
found that the effective dose of inhibition were in the range of2-200^ig/ml (IC50 = 
50^ig/ml) (Figure 3.7). 
3.3.4.2 Dose response curve ofwater extract ofPrunella vulgaris 
As for the Prunella vulgaris water extracts, the effective dose of inhibition 
were in the range of2-200^g/ml with an IC50 = 50^ig/ml (Figure 3.8). 
r 
110 
1 0 0「 
9。 / 
80 - I 
7Q -. / 
1 6。_ / 
r ° - . . / 
40 - / 
3 � J 
20 / 
10 - / 
o i J l l l l i 1 1 1 l l l l l l l l i 
0.00001 0.0001 0.001 0.01 0.1 1 
Methanol extract of W. unigemmata (mg/ml) 
Figure3.7 Dose response curve of Woodwardia unigemmata on inhibition to HIV 
protease. Percentage inhibition is calculated as the percentage of 
inhibition of fluorescence intensity in the presence and absence of 
extracts. Values are means 土 S.E.M，n=6 
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Figure 3.8 Dose response curve of Prunella vulgaris on inhibition to HIV 
protease. Percentage inhibition is calculated as the percentage of 
inhibition of fluorescence intensity in the presence and absence of 
extracts. Values are means 土 S.E.M，n=6. 
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3.3.4.3 Inhibition mode of methanol extract of Woodwardia unigemmata 
The methanol extract of woodwardia unigemmata was further tested for 
inhibition with various concentrations in order to characterize its mode of 
inhibition. Figure 3.7 shows the Lineweaver-Burk plot of the result. The apparent 
Km ofthe one with methanol extract of W. unigemmata was 0.098 mgy^ ml while the 
apparent Km without extract was 0.012mg/ml. 
3.3.4.4 Inhibition mode ofwater extract oiPrunella vulgaris 
The inhibition of Prunella vulgaris water extracts on various concentrations 
of substrates was shown in Figure 3.8. The slope of line where extract was added 
is greater than the one without extract. The apparent Km of the one with water 
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Fig^re 3.9 Mubition mode of Woodwardia unigemmata. The concentration of 
substrate used was 2.5^iM, 5^iM, lOpM，20^iM and 40^iM. The 
concentration of methanol extract of Woodwardia unigemmata used 
was O.lmg/ml. The circle is the inhibition to HTV PR without 
Woodwardia extract and the square is inhibition to HIV PR with 
Woodwardia extract. 
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figure 3.10 Miibition mode of Pruenlla vulgaris. The concentration of substrate 
"" used was 2.5^iM, 5^iM, lOp,M, 20^iM and 40fiM. The concentration of 
, methanol extract of Prunella vulgaris used was O.lmg/ml. The circle is 
the inhibition to HrV PR without Prunella extract and the square is 
inhibition to HIV PR with Prunella extract. 
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3.3.4.5 Effect of partially purified extracts on HIV protease inhibition 
The partially purified Prunella vulgaris extracts obtained from chapter 2 
having the WM RT inhibitory activity were also tested for inhibition to HTV 
protease. These extracts include the crude extract O.lM NaOH eluate from 
polyamide resin, methanol eluate from polyamide resin, eluate of Sephadex LH-20 
fraction 6 and RP-HPLC fraction 3. The preliminary result from the fluorometric 
assay found that the crude extract O.lM NaOH eluate from polyamide resin and 
Sephadex LH-20 eluate showed 80% to 92.5% inhibition. However, methanol 
eluate from polyamide resin and RP-HPLC fraction 3 were not very effective 
(13% to 23%) (Table3.3). RP-HPLC assay was done as well in order to confirm 
the cleavage site. No product peaks can be found in the assay with crude extract, 




Table 3.3 Effect of polyamide adsorption chromatography separation of Prunella 
vulgaris extract on inhibition to UN protease by fluorometric method 
Steps ofPurification % Inhibition % Inhibition 
(0.2mg/ml) (0.02mg/ml) 
Crude P. vulgaris extract 92.46 土 1.61 28.03 土 3 
Polyamide resin eluate (O.lM NaOH) 88.58 土 1.83 25 土 1.74 
Polyamide resin eluate (methanol) 23.2 土 2.41 3.03 土 1.55 
The eluate of polyamide adsorption chromatography of Prunella 
vulgaris extract was used in the assay at two doses (0.2mg/ml and 
0.02mg/ml). Percentage inhibition is expressed as the percentage 
inhibition of fluorescence intensity in the presence and absence of 
extracts in the fluorometric assay. The enzyme used was 6.5^g / well. 
Values are means 土 S.E.M.，n=6. 
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Figure 3.11 Effect of partially purified Prunella vulgaris extract on inhibition to 
fflV protease by RP-HPLC assay. (Al) 0.2mg/ml ofcrude extract. (A2) 
0.02mg/ml crude extract. (B1) 0.2mg/ml of O.lM NaOH eluate (B2) 
0.02mgAnl ofO.lM NaOH eluate. (C1) 0.2mg/ml methanol eluate (C2) 
0.02mg/ml methanol eluate. (D1) 0.2mg/ml of Sephadex LH_20 eluate. 
(D2) 0.02mg/ml Spehadex LH-20 eluate. (El) 0.2mgAnl RP-HPLC 
eluate. (E2) 0.02mg/ml RP-HPLC eluate. (F1) fflV protease assay without inhibitor. (F2) HIV protease assay with pepstatin A. 
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3.4 Discussion 
fflV protease is a new target for the treatment of ATOS. The enzyme is used 
for the cleavage ofproviral protein which is a polyprotein to structural protein and 
fUnctional enzyme. The processing of the polyprotein inside the virion particle 
completes the replication cycle of HIV-1. This mature virion particles are able to 
promote a new infection in an adjacent T-lymphocyte (Meek, 1992). Several 
protease inhibitors have been developed including Saquinavir, Ritonavir and 
Lidinavir. Saquinavir is being used in combination with other inhibitors for the 
combination therapy. However, these inhibitors may introduce several side effects 
such as diarrhea, nausea and even kidney stone (Phillips et al., 1996). 
The partially purified recombinant fflV protease was successfully prepared 
and the specificity and activities have been validated using two assay systems. The 
expressed fflV protease is expressed as inclusion body as demonstrated by the 
SDS-PAGE analysis (Figure 3.1). The molecular size is 11 kDa. The success in 
the preparation ofactive fflV protease facilitates our screening ofherbal extracts 
»-
for HTV protease inhibitory activities. 
r 
The substrate used for RP-HPLC is a synthetic peptide with sequence 
SQNYPVV-NH2. The sequence is based on the pl7/p24 cleavage site of HIV-l 
Pr55gag. The cleavage site is the Tyr-Pro bond. It has been used as a model 
substrate for assay ofHrV protease (Lin et al, 1994). Another HrV protease assay 
is by use of fluorogenic substrate. The sequence of this substrate is Arg-
Glu(EDANS)-Ser-Gln-Asn-Tyr-Pro-Ile-Val-Gln-Lys(DABCYL)-Arg. The 
cleavage site is the Tyr-Pro bond. The substrate contains a N-terminal fluorophore, 
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EDANS and a C-terminal quenching group, DABCYL. The cleavage of this 
peptide results in the release of DABCYL-linked peptide fragment so that the 
cleavage causes an increase in fluorescence intensity (Matayoshi et al, 1990). The 
advantage of fluorometric assay is high-through put, allowing the screening of a 
large number of samples in short period of time. The advantage of using RP-
HPLC assay is to confirm the specific cleavage site of HTV protease to the 
synthetic peptide by comparing the retention times of substrate and the product 
standard. However, the assay is time consuming. 
The increase in enzyme activities demonstrated that the enzyme activities are 
concentration dependent. The most suitable enzyme concentration for assay is 
6.5|ig of HIV protease because the fluorescence intensity gave a better signal -to 
noise ratio. Pepstatin A was used as a typical inhibitor for HTV protease. It is an 
aspartic protease inhibitor. The result shows that the enzyme was inhibited 
confirming that this enzyme belongs to aspartic protease and not other bacterial 
enzymes contaminated in the preparation. RP-HPLC is used in order to confirm 
that the cleavage on fluorogenic substrate is due to HTV protease activity. The 
enzyme activities can be demonstrated by appearance of standard product peak 
produced by HTV protease cleavage (Figure 3.2). Different concentrations of 
enzyme were tested in order to find the optimal conditions for the assay and the 
confirmation of the cleavage site. The result shows that the N-terminal fragment 
of the released product is indeed produced from cleavage of the substrate by this 
recombinant enzyme. The study indicates the specificity ofTyr-Pro bond cleavage. 
Moreover, it was found that the product peak increased with the increase in 
enzyme concentration indicating that the enzyme activities is concentration and 
time dependent. The most suitable concentration for RP-HPLC assay is using 
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19.5昭 ofenzyme per tube with 2 hour incubation at 37�C. Pepstatin A was added 
into the assay as control. It demonstrated that pepstatin A inhibited the enzyme. 
This further confirmed that the recombinant protease is fflV protease. 
The thirteen herbal extracts tested have previously been shown to be able to 
inhibit fflV infection in an in vitro assay (Chang et al., 1988). Here, the ability of 
these extracts to inhibit HIV PR were tested in order to illustrate the mechanism of 
actions. Both methanol and aqueous extract were screened. The result showed that 
these herbal extracts gave variable degree of inhibition to fflV PR suggesting that 
a certain degree ofselectivity ofthese extracts on fflV replication. From the result 
of fluorometric assay, it was found that extracts from Woodwardia unigemmata 
has the most potent inhibitory activity at concentration between 0.02-0.2mg/ml. 
The inhibitory activity was further confirmed by RP-HPLC. These data suggest 
that the inhibition of Woodwardia unigemmata methanol extract on HW infection 
(Chang et al., 1988) may be due to its effects on fflV protease. Similar inhibition 
was found in the water extracts of Woodwardia unigemmata. This suggested that 
the active components are present in both the methanol and aqueous extracts. For 
the aqueous extracts, it was found that only six of which showed inhibitory 
activities > 50% on ffiV PR. The result was compared to the result of a similar 
study reported by Xu et al (1996). Five herbal aqueous extracts which include 
Anadrographis paniculata, Chrysanthemum morifoUum, Coptis chinensis, 
Lithospermum erythrorhizon and Lonicerajaponica were tested in both studies. 
The discrepency is presently not clear but may be due to different sources ofherbs 
or difference in techniques for HW PR assay. Only Lonicera japonica shows 
similar result between two studies. The aqueous herbal extract which has the 
strongest inhibition on ffiV PR is Prunella vulgaris aqueous extract. Compared 
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this to the methanol extract of Prunella vulgaris, it was concluded that the 
inhibitory activities is predominantly present in the aqueous extract but not in the 
methanol extract. 
The extract that showed higher than 50% inhibition were selected for RP-
HPLC assay. The result of RP-HPLC assay for methanol extract is similar to the 
one found in ,fluorometric assay except Coptis chinesis and Viola yedoensis. No 
evidence of inhibition was found in the RP-HPLC analysis. The difference in the 
RP-HPLC assay for Coptis chinensis and Viola yedoensis and the fluorometric 
method may be due to quenching by some components present in Coptis chinensis 
and Violayedoensis to give a false positive inhibition. 
From the screening result, two herbal extracts were identified as leading 
extracts. Dose response curve of both Woodwardia unigemmata methanol and 
Prunella vulgaris aqueous extract were then carried out. The IC50 ofboth extracts 
were lower than New Zealand plant Pseudotsuga menziesii and Elaeocarpus 
hookeriams (9.63^g/ml and 9.74^igAnl respectively) (Wan et cd., 1996). The slope 
M 
ofthe line which represent the apparent Km had been calculated. It showed that the 
slope ofthe one with crude extracts were greater than the one without extract. 
As for the purified Prunella vulgaris aqueous extract similar but not identical 
activity which were previously shown to inhibit HIV RT can be found in the crude 
extract and O.lM NaOH eluate from polyamide resin. They inhibited HFV PR at 
concentration 0.2mg/ml. It suggests that the compounds that can inhibit HIV PR 
may also be polyphenolic compounds. The methanol eluate from polyamide resin 
did not show inhibition on HIV PR. The enzyme cannot be inhibited by methanol 
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eluate suggested that the compounds may not have much OH groups. The result of 
fluorometric assay was then compared with the RP-HPLC assay. The result was 
different to the fluorometric one. No product peak can be found when methanol 
eluate was added at the concentration 0.2mg/ml and the peak can be found at the 
concentration 0.02mg/ml. It may be due to quenching by the presence in these two 
eluates in fluorometric to give a false positive inhibition. 
At present, the active constituents of the extracts from Woodwardia 
unigemmata and Prunella vulgaris has not been identified. Therefore, further 





Chapter 4 General discussion 
AIDS is still a disease with no curable medication. Researchers have been 
searching for a better way to treat the disease. The natural products are alternative 
source for drug discovery. Moreover, once the structure is identified, it can be 
used for chemical modification so that a new drug can be developed. The 
discovery of .non-nucleoside inhibitors was based on the structure of natural 
products found in screening of active herbs. This study demonstrated that some 
herbal extracts show strong inhibition to HrV RT and HFV PR. The results show 
that water extract from Prunella vulgaris can inhibit both HTV RT and HTV PR. 
According to the literature from traditional Chinese medicine, this herb helps to 
disperse liver heat and dissolve accumulations. Traditional application of the herb 
is to treat goiter scrofula, conjuctivitis, carbuncle, incised-wound toxin, ocular 
swelling and pain, photophobia, excessive tearing, pinkish leukorrhea mixed with 
white matter (Hsu et al., 1986). The constituents of this herbs include tannins, 
oleanolic acid, ursolic acid, cis-caffeic acid and ions such as magnesium, 
manganese, potassium, sodium (Duke, 1992). Previous studies showed that 一 
anionic polysaccharide which is sulfated is the active compound that inhibit the 
growth ofHTV (Tabba et al., 1989). However, the actual mechanism of inhibition 
is not know. This study extends their findings by showing that the inhibition of 
HrV replication may be mediated through the inhibition ofboth HIV enzymes. 
The approach for identification of the active compounds was discussed by 
Hostettmann (1995). The first step is to select and collect the suitable plant 
materials, then to extract with suitable solvent. Biological and pharmacological 
screening of crude extracts was done after extraction in order to find out the 
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leading extract. Then, several chromatographic separation was done to separate a 
pure constituent which was demonstrated by bio-assay. These steps were followed 
and it was found that the active components in the extract was characterized as the 
polyphenolic compounds with polysaccharide on these compounds. The result was 
different from the previous studies suggested that there are many active 
compounds that can inhibit the growth ofHTV. 
Many attempts were tried to purify the components in the extract including 
several chromatographic separation. The first step is removal of tannins in the 
herbs. It is because tannins and other polyphenolic compounds are potent reverse 
transcriptase inhibitor. The removal of this compounds is to find out the new, non-
polyphenolic inhibitory compounds (Tan et al., 1991). From the methanol eluate 
and O.lM NaOH eluate form polyamide resin, it was found that the potent 
inhibitory compounds was polyphenolic compounds but not the non-tannin 
compounds with two or three phenolic hydroxyl groups (Tan et aL, 1991). This 
eluate then pass through two more chromatographic steps. Folin-Ciocalteu reagent 
was used to detect phenolic compound, the blue spot with a Rf of 0.266 一 
disappeared and the length of blue smear decreased. These results suggested that 
I* 
the amount of phenolic compounds decreased during the purification steps without 
abolish the inhibitory activity. The removal of polysaccharide did not affect the 
inhibitory activity indicated that the polysaccharide exist in plant is not important 
for fflV RT inhibition. 
Two leading plant extracts were found including methanol extract of 
Woodwawardia unigemmata and aqueous extract of Prunella vulgaris. Since 
Prunella vulgaris extract is inhibitory to HIV PR as well as HIV RT, several steps 
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of eluate were used and it was found that all the fractions can inhibit HTV PR 
suggesting that the active constituents may be structurally similar to the inhibitory 
activity to HTV RT. For the methanol extract of Woodwardia unigemmata, the 
active constituents have not been further characterized. The inhibition of both 
methanol and aqueous extract of Woodwardia unigemmata to HrV PR were 
similar suggesting that the active constituents are present in both extract. The 
effective concentration of Woodwardia unigemmata methanol extract is similar to 
those reported by Wan et al. (1996) and screening of traditional medicine 
currently used for treatment of various human disease in China, Japan and 
Indonesia. fXu et al, 1996). The chemical properties of the active constituent in 
these herbs are at present not clear. 
Li this study, only partially purified extracts were obtained. Further 
characterization is necessary in order to know the action mechanism of these 
activities. The toxicity of the compound should be carried out once purified 
compounds are identified. Attempt have been tried to determine the molecular 
weight of the active fraction from RP-HPLC by electrospray mass spectroscopy •“ 
(see Appendix 2). Preliminary results of molecular weight of unhydrolyzed active 
t 
fraction from RP-HPLC obtained from electrospray mass spectroscopy was about 
1700 while the acid hydrolyzed active fraction from RP-HPLC was about 1100. 
Further chemical characterization is necessary in order to determine the structural 
feature of this polyphenolic active constituent. 
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Appendix 3 Calibration curve for the determination of HIV protease 
concentration 
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